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57 ABSTRACT 
The invention relates to novel competitive immunoassays 
that are useful in detecting and quantitatively measuring 
analytes down to the nanomolar range. The invention also 
includes methods of selecting antibodies from libraries of 
polypeptides expressed on a cell Surface. In conducting 
immunoassays, anti-analyte antibody molecules are 
expressed on the Surface of a bacterial cell and then used to 
bind with labeled analyte. Quantitation is performed by 
competitively displacing the bound labeled analyte with a 
known amount of analyte and measuring the label. The 
method is rapid and inexpensive and may be performed with 
readily available Safe labeling reagents Such as fluorescent 
compounds. 
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ANTIBODY SELECTION METHODS USING 
CELL SURFACE EXPRESSED LIBRARIES 
This application is a continuation-in-part of U.S. Ser. No. 
08/258,543, filed Jun. 10, 1994, now abandoned which is a 
divisional of application Ser. No. 07/794,731, filed Nov. 15, 
1991, now U.S. Pat. No. 5,348,867 issued Sep. 20, 1994, all 
of which is incorporated by reference without disclaimer. 
The Government has rights in the present invention 
pursuant to National Science Foundation grant number 
BCS-94125O2. 
BACKGROUND OF THE INVENTION 
I. Field of the Invention 
The invention relates generally to antibody Selection and 
immunoassay technology and Specifically to remarkably 
efficient and rapid polypeptide library Screening methods. 
The invention also includes competitive immunoassays for 
analyte detection. The disclosed methods open the way for 
production of kilogram quantities of antibodies from inex 
pensively maintained microorganism cultures. 
II. Description of Related Art 
Antibodies are of increasing importance in human 
therapy, assay procedures and diagnostic methods. However, 
methods of identifying antibodies and production of anti 
bodies is often expensive, particularly where monoclonal 
antibodies are required. Hybridoma technology has tradi 
tionally been employed to produce monoclonal antibodies, 
but these methods are time-consuming and result in isolation 
and production of limited numbers of Specific antibodies. 
Additionally, relatively Small amounts of antibody are pro 
duced; consequently, hybridoma methods have not been 
developed for a large number of antibodies. This is unfor 
tunate as the potential repertoire of immunoglobulins pro 
duced in an immunized animal is quite high, on the order of 
>10', yet hybridoma technology is too complicated and 
time consuming to adequately Screen and develop large 
number of useful antibodies. 
One approach to this problem has been the development 
of library screening methods for the isolation of antibodies 
(Huse et al., 1989; McCafferty et al., 1990; Chiswell & 
McCafferty, 1992; Chiswell & Clackson, 1992; Clackson, 
1991). Functional antibody fragments have been produced 
in E. coli cells (Skerra & Pluckthun, 1988; Better et al., 1988; 
Orlandi et al., 1989; Sastry et al., 1989) as “libraries” of 
recombinant immunoglobulins containing both heavy and 
light variable domains (Huse et al., 1989). The expressed 
proteins have antigen-binding affinity comparable to the 
corresponding natural antibodies. However, it is difficult to 
isolate high binding populations of antibodies from Such 
libraries and where bacterial cells are used to express 
Specific antibodies, isolation and purification procedures are 
usually complex and time-consuming. 
Combinatorial antibody libraries generated from phage 
lambda (Huse et al., 1989) typically include millions of genes 
of different antibodies but require complex procedures to 
screen the library for a selected clone. Methods have been 
reported for the production of human antibodies using the 
combinatorial library approach in filamentous bacterioph 
age. A major disadvantage of Such methods is the need to 
rely on initial isolation of the antibody DNA from peripheral 
human blood to prepare the library. Moreover, the genera 
tion of human antibodies to toxic compounds is not feasible 
owing to risks involved in immunizing a human with these 
compounds. 
Currently the most widely used approach for Screening 












face of filamentous bacteriophage (Smith, 1991; Smith, 
1992). The polypeptides are expressed as fusions to the 
N-terminus of a coat protein. AS the phage assembles, the 
fusion proteins are incorporated in the viral coat So that the 
polypeptides become displayed on the bacteriophage Sur 
face. Each polypeptide produced is displayed on the Surface 
of one or more of the bacteriophage particles and Subse 
quently tested for Specific ligand interactions. While this 
approach appears attractive, there are numerous problems, 
including difficulties of enriching positive clones from 
phage libraries. Enrichment procedures are based on Selec 
tive binding and elution onto a Solid Surface Such as an 
immobilized receptor. Unfortunately, avidity effects arise 
due to multivalent binding of the phage and the general 
tendency of phage to contain two or more copies of the 
displayed polypeptide. The binding to the receptor Surface 
therefore does not depend Solely on the Strength of interac 
tion between the receptor and the displayed polypeptide. 
This causes difficulties in the identification of clones with 
high affinity for the receptor; thus, there remain distinct 
deficiencies in the methods used to isolate and Screen 
polypeptides, particularly antibodies, even in View of the 
development of phage libraries. 
Moreover, there is a significant need for procedures that 
are rapid and inexpensive relative to cost of currently used 
techniques. 
Immunoassays have typically been used for the detection 
of antigens or antibodies, less frequently for determination 
of other classes of compounds. Immunoassays can be gen 
erally divided into two types: heterogeneous assays requir 
ing multiple Separation Steps, and homogeneous assays 
which are performed directly. Heterogeneous immunoassays 
in general involve a ligand or antibody immobilized on a 
Solid matrix. A Sample containing an analyte is contacted 
with the immobilized antibody and the amount of complex 
formed on the matrix Support is determined from a label 
attached directly or indirectly to the immobilized complex. 
Heterogeneous immunoassays may be performed as Sand 
wich assays in which a molecule of interest is reacted with 
an immobilized antibody that specifically binds that mol 
ecule with high affinity. In a Second Step, a conjugate formed 
from the same or different antibody to the antigen and a 
marker molecule is reacted with the antigen-antibody com 
plex on the immobilization matrix. After removal of exceSS 
free marker conjugate, the bound marker conjugate, which is 
proportional to the amount of analyte in the Sample, is 
measured. 
ELISA or enzyme-linked immunosorbent assay is one 
example of an immunoassay. ELISAS are extensively used 
in biotechnology applications, particularly as immunoassays 
for a wide range of antigenic Substances. The Sensitivity of 
ELISA is based on the enzymatic amplification of the Signal. 
However, despite Such widespread use, ELISA has Sev 
eral disadvantages, including inconvenience and expense 
that preclude more general use. Additionally, immunoassays 
depend on the availability of antibodies, which is frequently 
a major consideration in terms of cost or feasibility of a 
Specific assay. Several Washing Steps may often be required 
in ELISA procedures to remove excess antibody not bound 
to the immobilization Support or to remove exceSS analyte or 
antibody following the primary binding reaction. The Steps 
necessary to remove exceSS enzyme-conjugate that does not 
bind to the immobilized antibody-analyte complex may 
Significantly increase assay time and cost. 
There has been some effort to provide semi-automation of 
ELISA, for example the apparatus and method described in 
5,866,344 
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U.S. Pat. No. 4,981,785. However, these methods involve 
not only the expense of the equipment and training of 
Specialized perSonnel, but also fail to provide rapid and 
economical quantitation of analytes. 
Unfortunately, alternative analytical methods for quanti 
tative determination of trace amounts of many analytes, 
including not only polypeptides but also organic Species 
Such as toxic chemicals, typically involve relatively com 
pleX and inconvenient procedures. In most cases, Samples 
must be collected, extracted and prepared for Specific analy 
SeS. Procedures frequently involve use of hazardous chemi 
cals. Such as organic Solvents and/or radioactive material, 
thereby adding to cost. 
Recent advances in biotechnology, Specifically the advent 
of monoclonal antibodies and the use of enzyme labels in 
place of radiolabels, have promoted a rapid expansion of 
immunoassay applications to include the detection of certain 
toxic chemicals (Collins, 1985; Gould and Marx, 1988; 
Stanker, 1989; Watkins, 1989; Roberts, 1989). Enzyme 
labels, for example, are particularly useful because the 
catalytic properties of the enzyme provide powerful bio 
chemical amplification, thereby allowing detection of 
extremely low analyte concentrations. However, the utility 
of this type of detection may be limited if the binding site of 
the antibody is not available or the Sample Solution contains 
interfering Substances. 
Enzyme-amplified immunoassay techniques have been 
applied to the determination of different drug species. In this 
System a hapten-enzyme conjugate is prepared So that 
enzyme activity is retained after conjugation. When the 
conjugate binds with the hapten-specific antibody there is a 
loss in enzyme activity. Any free hapten (drug) in a sample 
reduces the inhibition by competing for antibody binding 
Sites. Enzyme activity is thus proportional to concentration 
of free hapten. This type of assay has been developed by the 
Syva Company (Palo Alto, Calif.) under the trademark 
EMIT. However, the EMIT assay is less satisfactory for 
detection of relatively large molecules Such as proteins. 
Immunodetection technology employing Solid phase 
enzyme immunoassay for detection of certain environmental 
waste by-products has been reported (Huber, 1985). For 
example, the agricultural chemical Atrazine was reported 
detectable in the 1.1 to 2200 ppb range. Enzyme immunoas 
Say (EIA) Sensitivity was further improved by using spheres 
as antibody carriers and by using affinity purified antibodies. 
While this is a step forward in the ability to detect low levels 
of environmental contaminants, the procedures are time 
consuming and costly. 
Immunoassays represent a powerful technique for the 
identification and quantification of Specific molecules. Radio 
Immunoassay (RIA) and ELISA techniques currently form 
the basis of many medical diagnostic procedures. However, 
Solid phase immunoassays rely on isolated and purified 
antibodies that may be prohibitively expensive. In cases 
where the detection reagent is an enzyme or radiolabeled 
material, additional considerations are Safety, equipment and 
technical manpower cost. 
Despite Some progreSS and ongoing efforts to expand the 
availability and identification of useful antibodies for 
immunoassays, there is a lack of rapid and inexpensive 
antibody Screening methods. Available technologies have 
failed to provide means to cost effectively produce large 
quantities of Such antibodies. Additionally, despite the wide 
application of immunoassay methods, most are complex, 
often Slow and frequently employ hazardous reagents. 
SUMMARY OF THE INVENTION 
The present invention addresses these and other draw 











antibody selection and production. For the first time it is 
possible to rapidly Screen polypeptide libraries for potential 
antibodies; often in a matter of hours. The disclosed methods 
allow production of large quantities of antibodies, poten 
tially on a kilogram Scale, from microorganism cultures. 
And, because Selected antibodies can be displayed on the 
Surface of a host cell, immunoassays can be conducted with 
remarkable rapidity. 
In one aspect of the invention, eXpression libraries are 
prepared Such that an expressed protein is displayed on the 
Surface of a cell. Typically the polypeptides will be Surface 
expressed in a host cell Such as bacterial, yeast, insect, 
eukaryotic or mammalian cells. Gram negative bacterial 
cells are preferred, particularly E. coli, although Salmonella, 
Klebsiella, Erwinia, Pseudomonas aeruginosa, Haemophi 
lus influenza, Rickettsia rickettsii, Neisseria gonorrhea, etc 
are also expected to be suitable. While examples have 
utilized a bacterial host cell for Surface expression, it is 
contemplated that other microorganisms may prove useful; 
for example, yeasts, molds, algae, eukaryotes, as well as 
other prokaryotes and Single cell microorganisms. 
Surface expression of a polypeptide, e.g. antibody, on a 
cell Surface is achieved using a recombinant vector that 
promotes display on the outer membrane of a host cell. 
Vectors are Such as those of the general construction 
described in U.S. Pat. No. 5,348,867, incorporated herein by 
reference. Generally the vectors will be appropriate for a 
bacterial host cell and will include at least three DNA 
Segments as part of a chimeric gene. One Segment is a DNA 
Sequence encoding a polypeptide that targets and anchors a 
fusion polypeptide to a host cell Outer membrane. A Second 
DNA segment encodes a membrane-transversing amino acid 
Sequence, i.e. a polypeptide that transports a heterologous or 
homologous polypeptide through the host cell Outer mem 
brane. The third DNA segment encodes any of a number of 
desired polypeptides. 
Such vectors will display fusion polypeptides at the 
exterior of a host cell. These recombinant vectors include a 
functional promoter Sequence. 
Expression of recombinant proteins Such as antibodies or 
antibody fragments on the cell Surface of gram-negative 
bacteria is achieved by fusion to Segments of a major 
lipoprotein and Omp A; however, fusion to protein domains 
other than those derived from the major lipoprotein and 
OmpA is also envisioned, provided that these domains can 
function for the expression of the desired polypeptide on the 
cell Surface. Generally, the desired antibody, antibody frag 
ment or peptide is fused to an amino acid Sequence that 
includes the Signals for localization to the outer membrane 
and for translocation across the Outer membrane. The amino 
acid Sequences responsible for localization and for translo 
cation across the outer membrane may be derived either 
from the same bacterial protein or from different proteins of 
the same or different bacterial Species. Examples of proteins 
that may serve as Sources of localization Signal domains are 
shown in Table 2. 
TABLE 2 
EXAMPLES OF OUTER MEMBRANE TARGETING SEQUENCES 
Organism 
Lipp E. coli (or functional 
equivalent in Salmonella) 
TraT E. Coli (or functional 




EXAMPLES OF OUTER MEMBRANETARGETING SEOUENCES 
Organism 
Osm E. coli (or functional 
equivalent in Salmonella) 
N1pB E. coli (or functional 
equivalent in Salmonella) 
Blaz, E. coli (or functional 
equivalent in Salmonella) 
Lpp1 Pseudomonas aeruginosa 
PA1 Haemophilus influenza 
OprI 
17 kDa lipp Riokettsia riokettsii 
H.8 protein Neisseria gonorrhea 
In addition a Sequence that allows display of the polypep 
tide on the cell Surface is required. Appropriate examples are 
shown in Table 3. 
TABLE 3 
EXAMPLES OF TRANSMEMBRANE SEOUENCES 
Omp A E. coli or functional 
equivalent in Salmonella 
LamB E. coli or functional 
equivalent in Salmonella 
Phoe E. coli or functional 
equivalent in Salmonella 
OmpC E. coli or functional 
equivalent in Salmonella 
OmpF E. coli or functional 
equivalent in Salmonella 
OmpT E. coli or functional 
equivalent in Salmonella 
FepA E. coli or functional 
equivalent in Salmonella 
Of course Similar considerations also apply to host cells 
other than bacteria, including eukaryotic, yeast, molds, etc. 
as previously discussed. 
Screening for antibodies employing the methods of the 
present invention allows one to Select an antibody or anti 
body fragment from a plurality of candidate antibodies that 
have been expressed on the Surface of a host cell. In most 
instances the host cell will be a bacterial cell, preferably E. 
coli. The antibodies are obtained from an expression vector 
library that may be prepared from DNAS encoding antibod 
ies or antibody fragments. One source of such DNAS could 
be from an animal immunized with a Selected antigen; 
alternatively, antibody genes from other Sources can be used, 
Such as those produced by hybridomas or produced by 
mutagenesis of a known antibody gene. One preferred 
method of obtaining DNA segments is to isolate mRNA 
from antibody cells of an immunized animal. The mRNA 
may be amplified, for example by PCR, and used to prepare 
DNA segments to include in the vectors. One may also 
employ DNA segments that have been mutagenized from 
one or more DNAS that encode a selected antibody or 
antibody fragment. 
Once an antibody expression library is prepared, the 
Selected antigen for which one desires to identify and isolate 
specific antibody or antibodies is labeled with a detectable 
label. There are many types of detectable labels, including 
fluorescent labels, the latter being preferred in that they are 
easily handled, inexpensive and nontoxic. The labeled anti 
gen is contacted with the cells displaying the antibody 











antigen-antibody binding. Conditions can be varied So that 
only very tightly binding interactions occur; for example, by 
using very low concentrations of labeled antigen. 
Identifying the antibody or antibody fragment expressing 
cells may be accomplished by methods that depend on 
detecting the presence of the bound detectable label. A 
particularly preferred method for identification and isolation 
is cell Sorting or flow cytometry. On aspect of this method 
is fluorescence activated cell sorting (FACS). 
Identification of antibody expressing bacteria by FACS is 
directly based on the affinity for the soluble hapten thus 
eliminating artifacts due to binding on Solid Surfaces. This 
means only the high affinity antibodies are recovered by 
Sorting following binding of low concentrations of fluores 
cently labeled antigen. There is no analogous method for 
Specifically Selecting phage with very high affinity. 
Additionally, the Sorting of positive clones is essentially 
quantitative. It is limited only by the accuracy of the flow 
cytometer which is on the order of 95%. In contrast with 
phage technology, the efficiency of Selection is not limited 
by avidity effects because Screening does not depend on 
binding to a Surface having multiple attachment Sites. 
Following Selection of high affinity clones, the production 
of soluble antibodies can be achieved easily without the 
need for further Subcloning Steps. Thus, the clones may be 
maintained under Standard culture conditions and employed 
to produce the selected antibody. Production of antibody is 
limited only to the Scaleup of the cultures. 
The invention further includes competitive binding assays 
using cells with antibodies or analyte-combining antibody 
fragments expressed on the outer cell Surface. 
AS used in the context of the present invention, analyte is 
defined as a species that interacts with a non-identical 
molecule to form a tightly bound, Stable complex. For 
practical purposes, the binding affinity is usually greater than 
about 10M and is preferably in the range of 
10°-10'M'. The analyte may be any of several types of 
organic molecules, including alicyclic hydrocarbons, poly 
nuclear aromatics, halogenated compounds, benzenoids, 
polynuclear hydrocarbons, nitrogen heterocyclics, Sulfur 
heterocyclics, oxygen heterocyclics, and alkane, alkene 
alkyne hydrocarbons, etc. Biological molecules are of par 
ticular interest, including amino acids, peptides, proteins, 
lipids, Saccharides, nucleic acids and combinations thereof. 
Of course it will be understood that these are by way of 
example only and that the disclosed immunoassay methods 
are applicable to detecting an extraordinarily wide range of 
compounds, So long as one can obtain an antibody that binds 
with the analyte of interest. 
The disclosed whole cell immunoassay methods allow 
rapid detection of a wide range of analytes and are particu 
larly useful for determination of polypeptides. The methods 
have been developed to take advantage of the binding 
characteristics of bacterial cell Surface exposed anti-analyte 
antibodies. Such Surface displayed antibodies are stable and 
bind readily with specific analytes. This unique form of 
protein expression and immobilization thus has provided the 
basis of an extremely rapid competitive assay that may be 
performed in a Single reaction vessel in an "add and mea 
Sure' format. Such assays can be described as “one-pot' 
reactions that make possible in Situ detection of an analyte. 
A particular advantage of cell Surface expressed antigen 
binding antibodies is that the antibody is attached to the 
outer membrane of the cell. The cells therefore act as a Solid 
Support during the assay, thereby eliminating many of the 
manipulations typically required in preparing reagents 
5,866,344 
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required for existing immunoassay techniques. Optionally, 
cells with the antibody displayed on the Surface may them 
Selves be attached to a Solid Support Such as a membrane, 
dipstick or beads to further facilitate removal of the cells 
following the assay. 
The immunoassays of the present invention may be used 
to quantitate a wide range of analytes. Generally, one first 
obtains the appropriate host cell culture where the anti 
analyte antibody is displayed on the host cell Surface, 
calibrates with Standard Samples of analyte, then runs the 
assay with a measured Volume of unknown concentration of 
analyte. 
In conducting a competitive immunoassay in accordance 
with the disclosed methods, one first obtains a gram negative 
host cell that expresses an analyte binding antibody. The 
host cell is then contacted with a Standard analyte Sample 
that contains a known amount of an analyte linked to a 
detectable label employing conditions effective for forming 
an immune complex. Once calibration is completed, the 
Same procedure is used with a Second host cell that has the 
Same antibody or analyte-combining fragment expressed on 
its Surface, except that in addition to the Standard labeled 
analyte Sample, a test Sample in which an unknown amount 
of analyte is to be determined is added. One is not limited 
to using the same host cell in this procedure. 
In the actual assay, a known amount of the antibody 
covered cells are placed in a Solution of a known concen 
tration of the analyte-conjugate along with an unknown 
concentration of the analyte (the test Solution). The analyte 
conjugate competes with free analyte in Solution for binding 
to the antibody molecules on the cell Surface. The higher the 
concentration of analyte conjugate in the Solution, the fewer 
molecules of fluorescein analyte conjugate bind on the 
Surface of the cells, and Vice versa. 
The mixture is centrifuged to pellet the cells, and the 
fluorescence of the Supernatant is measured. The assay is 
quantitative because the amount of observed fluorescence is 
proportional to the concentration of analyte in the test 
Sample, i.e., if there is a very low concentration of analyte 
to compete with the fluorescein conjugate, then most of the 
conjugate will bind to the cells and will be removed from 
Solution. The more molecules of analyte in Solution, the 
more molecules of analyte bind to the antibodies thereby 
preventing the conjugate from binding. In this case, more 
fluorescein conjugate remains in the Supernatant to give a 
Stronger fluorescence Signal. The assay can be calibrated to 
generate a quantitative measurement of the unknown con 
centration of analyte. The entire assay requires less than one 
hour. Fluorescence determinations may be made with a basic 
fluorimeter. 
Gram negative host cells are preferred in the practice of 
the invention. Generally one will wish to use E. coli or 
Salmonella and to Surface-express an analyte-binding anti 
body suitable for determination of a selected antigen. Meth 
ods for Surface-expression of a wide range of polypeptides 
are found in U.S. Pat. No. 5,348,867, incorporated herein in 
its entirety by reference. Virtually any antibody may be 
Surface expressed in this manner, including antibodies fused 
to polypeptides, catalytic antibodies and multi-antibody 
fusions. 
AS used herein, the term “contacting” is defined as 
bringing the reaction components into close enough proX 
imity to each other to allow the desired reaction to occur. 
Contacting may be by mixing the components in Solution, 
for example, or by heterogeneous interaction Such as by flow 
contact through a column or immobilizing matrix that binds 











In preferred embodiments the immunoassay is performed 
to quantitate the amount of analyte in a Sample. Cells 
Surface-expressing an analyte-combining antibody are pref 
erably incubated with limiting concentrations of an analyte, 
preferably labeled. Any of a wide variety of labels may be 
employed; however, fluorescence labels are particularly 
preferred for the several advantages over other labels. For 
example, enzyme labels may not be accurate if enzyme 
activity is compromised, Such as from Solution contami 
nants, radiolabels are not only expensive but also pose a 
hazard. Safety precautions are usually required by law and 
may be quite Stringent. In contrast, fluorescence labels are 
relatively inexpensive and, more significantly in terms of 
cost, can be detected using only a basic fluorimeter rather 
than more complicated and costly instrument. 
The competitive immunoassay discussed above requires 
one to Set up a control Sample. This Sample comprises a 
Second host cell expressing an analyte binding antibody. 
This is contacted with a known amount of analyte linked to 
a detectable label and a known amount of unlabeled analyte, 
i.e. the analyte to be detected or determined in the assay. 
After formation of the immunocomplexes, one measures the 
free label in solution after the cells have been separated. This 
measures the amount of residual detectable label as the 
decrease in, e.g., fluorescence emission, from which the 
amount of unknown analyte may be determined. A preferred 
fluorescent label is fluorescein. The inventors have found 
that measurement of the amount of residual label that is not 
bound to antibodies is proportional to the amount of analyte 
label in solution. This provides the basis for quantitative 
measure in that the increase in the amount of label is directly 
proportional to the analyte. Alternatively, the label may be 
measured in the complexes. In this type of measurement, the 
analyte is inversely proportional to the amount of label. 
Of course fluorescence labeling, while preferred, does not 
preclude the use of other detectable agents Such as chemi 
luminescent agents, electrochemiluminescent agents, radio 
active labels, enzymatic labels that form a colored product 
with a chromogenic Substrate as well as other fluorescent 
compounds. A preferred fluorescent label is fluorescein 
while Ru(bpy)" is preferred for use as an electrochemilu 
minescent agent. 
The invention is readily adaptable to the determination of 
multiple analytes. This is achieved using two or more 
different analyte-binding antibodies expressed in Separate 
host cells. It is also possible to Surface express more than one 
antibody on the Surface of a particular host cell; however, 
this may cause interference in binding. One will, in these 
Situations, use different detecting agents, for example, two 
different fluorescent labels, each with distinct emissions, 
Such as fluorescein which emits at 520 nm and Texas Red 
which emits at 620 nm. 
Also included as part of the invention are expression 
vector libraries. Such libraries include cells that Surface 
display a plurality of antibodies or antibody fragments. 
Gram negative cells are preferred, particularly E. coli. The 
antibody or antibody fragments will have distinct antigen 
combining regions or metal binding Sites. The Surface 
displayed antibodies may be catalytic antibodies or antibody 
conjugates Such as fusion proteins that include reporter 
molecules, e.g. alkaline phosphatase, luciferase, 
B-lactamase, etc. 
In certain aspects of the invention, host cells displaying an 
antibody or antibodies on the Surface may be used to 
Stimulate an immune response. Such responses will be 
obtained by administering to an animal a pharmaceutical 
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composition that includes an immunologically effective 
amount of a host cell, preferably Gram negative and more 
preferably E. coli, that expresses an antibody or antigen 
combining antibody fragment on its outer membrane Sur 
face. 
AS part of the invention, immunoassay kits are also 
envisioned comprising a container having Suitably aliquoted 
reagents for performing the foregoing methods. For 
example, the containers may include one or more bacterial 
cells with particular Surface expressed analyte-binding anti 
bodies. Suitable containers might be vials made of plastic or 
glass, various tubes Such as test tubes, metal cylinders, 
ceramic cups or the like. Containers may be prepared with 
a wide range of Suitable aliquots, depending on applications 
and on the Scale of the preparation. Generally, this will be an 
amount in conveniently handled form, Such as freeze-dried 
preparations, and Sufficient to allow rapid growth of the 
bacterial cells as required. 
Such kits may optionally include Surface-expressed anti 
bodies in host cells that are immobilized on Surfaces appro 
priate for the intended use. One may for example, provide 
the cells attached to the Surface of microtiter plates, adsor 
bent resins, cellulose (e.g. filter paper), polymers, glass 
beads, etc. 
For certain applications a kit containing a population of 
viable gram negative host cells that express a distinct 
analyte-binding antibody and also including a Sample of 
analyte linked to a detectable label is envisioned. Analyte 
Standards of the analyte may be included. 
The disclosed methods offer numerous advantages over 
current practice, not the least of which is the adaptation to 
production of large quantities of antibodies. The 
convenience, Safety and low-cost of bacterial cultures are 
important in commercial considerations. The Screening and 
assay methods are rapid, Simple and may be set up with 
relatively low capitalization cost as the equipment required 
is low-maintenance and does not require highly technically 
trained perSonnel to operate. 
Other objects, features and advantages of the present 
invention will become apparent from the following detailed 
description. It should be understood, however, that the 
detailed description and the Specific examples, while indi 
cating preferred embodiments of the invention, are given by 
way of illustration only, Since various changes and modifi 
cations within the Spirit and Scope of the invention will 
become apparent to those skilled in the art from this detailed 
description. 
BRIEF DESCRIPTION OF THE DRAWINGS 
The drawings form part of the present Specification and 
are included to further demonstrate certain aspects of the 
present invention. The invention may be better understood 
by reference to one or more of these drawings in combina 
tion with the detailed description of specific embodiments 
presented herein. 
FIG. 1A and FIG. 1B. Nucleotide and amino acid 
Sequence of the anti-digoxin Single chain F antibody frag 
ment. 
FIG. 2A. Western blot analysis of total membrane frac 
tions from E. coli JM109 cells containing pTX101 (Lanes 2 
and 4); JM109/pTX152 (Lanes 3 and 5) and probed with 
anti-Omp A antibodies at 1:5000 dilution; Lanes 4 and 5 
were probed with monoclonal anti-HSV antibodies at 
1:5000 dilution. Arrowheads indicate the Lpp-Omp A-B- 
lactamase fusion (lane 2) and the Lpp-Omp A-ScFV(digoxin) 
fusion (lane 3). The 32 kDa band in lanes 2 and 3 corre 











FIG. 2B. Lysate and whole cell ELISAS of JM109 cells 
containing plasmid pTX101 (solid) or pTX152 (hatched). 
Samples were incubated on microtiter wells coated with 
digoxin-conjugated BSA and probed with anti-B-lactamase 
(pTX101) or anti-HSV (pTX152) antibodies. Absorbance 
readings were referenced to Wells that were untreated with 
either lysates or whole cells. 
FIG. 3A. Phase contrast micrograph of JM109/pTX152 
cells after 1 hr of incubation with 107M digoxin-FITC. 
FIG. 3B. Micrographs of the same field as in FIG. 3A of 
JM109/pTX152 cells after a 1 hour incubation with 107M 
digoxin-FITC. 
FIGS. 4A-4G. Histogram data from FACS. The bar in 
each graph represents the Sorting gate or the fluorescence 
intensity defined as a positive event. The Sorting gate was 
chosen to maximize the number of positive events while 
minimizing the number of negative events within the win 
dow. All samples were labeled with 10-7M digoxin FITC. 
FIG. 4A. JM109/pTX152 sample used as a negative 
control. 
FIG. 4B. JM109/pTX152 sample used as a positive con 
trol. 
FIG. 4C. JM109/pTX152 pretreated with 0.2 mg/ml 
trypsin. 
FIG. 4D. JM109/pTX152 pretreated with free digoxin. 
FIG. 4E. A 100,000:1 mixture of JM109/pTX101:JM109/ 
pTX152 prior to the first cell sorting run. 
FIG. 4F. A 100,000:1 mixture after growing cells recov 
ered from the first cell Sorting run. 
FIG. 4G. A 100,000:1 mixture after growing cells recov 
ered from the Second cell Sorting run. 
FIG. 5. The sequences of the primers used for the PCR 
amplification of mRNA isolated from spleen cells for the 
construction of Single chain antibody libraries from immu 
nized animals. 
FIG. 6. Whole cell immunoassay using 0.5 nM FITC 
labeled digoxin. 
DETAILED DESCRIPTION OF PREFERRED 
EMBODIMENTS 
Antibody Screening Methods 
The development of methods that allow cell surface 
display of Virtually any polypeptide on the Surface of a host 
cell, and particularly to achieve Stable anchoring and 
polypeptide display on the Surface of a bacterial cell Such as 
E. coli, has provided the basis for new methods of rapid and 
efficient selection of antibodies from antibody libraries 
expressed in the host cells. Likewise, bacterial Surface 
displayed peptide libraries may be analogously employed to 
identify new antigens or epitopes to an antibody. 
The novel methods herein disclosed are particularly 
advantageous because they allow unprecedented rapid and 
efficient Selection, purification and Screening of polypeptide 
libraries from bacterial host cell Surfaces, providing Several 
advantages over phage libraries. Unlike most other methods 
used for Screening and assay, the disclosed methods are 
well-Suited for commercial adaptation. 
Expense is a major consideration in commercial produc 
tion. The methods herein disclosed employ bacterial cells 
Such as E. coli. These cells are inexpensive to produce and 
are convenient to work with. Kilogram quantities of cells 
can be produced overnight for a few dollars worth of media. 
Antibodies used in current immunoassays may cost S100/ 
gm or more to produce; total costs are even higher once 
purification and perSonnel costs are factored in. 
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ASSay procedures are greatly facilitated because antibod 
ies are displayed on the Surface of cells. This permits use of 
Simple centrifugation to remove the cells from an assay 
Sample. ASSays are thus very rapid, and inexpensive because 
centrifugation does not require complex or expensive equip 
ment. 
Bacterial cells in which antibodies have been expressed 
may be readily immobilized, thus allowing rapid recovery 
and efficient removal from the System. One may use 
membranes, dipsticks or beads through a chemically pro 
moted coupling reaction in addition to other well-known 
immobilization matrices. In this manner, the cells can be 
Separated from the Solution without the need for a centrifu 
gation Step. 
Bacterial cultures may be Supplied in forms that have an 
indefinite shelf life and yet can be readily prepared for use; 
for example as “stab cultures' or lyophilized preparations, 
the user may prepare large amounts in liquid culture as 
needed. The reagent is thus renewable as compared with the 
current antibody reagents that are “used up' and must be 
continually replaced. Bacterial cultures may be prepared 
fresh without concern about shelf-life of reagents that must 
be Stored until use. 
Many current immunoassays use radioactive agents or 
relatively complex equipment, e.g., polarizing fluorimeters. 
The disclosed assay methods require relatively inexpensive 
cell culturing equipment, a clinical centrifuge, and in one 
aspect of the assay, a fluorimeter. Daily assay costs are 
negligible, without concerns about radioactivity or other 
toxic materials, or expensive maintenance contracts and 
downtime that are frequent concerns in using complex 
equipment. 
The Screening methods are practiced by first constructing 
an antibody library using any of Several well-known tech 
niques for library construction. For example, after Selecting 
an immunogen, one may immunize a mammal by conven 
tional means and collect antiserum. mRNA from Spleen may 
be used as template for PCR amplification; for example 
employing primers complementary to constant and variable 
domain framework regions of different antibody Subclasses. 
Alternatively DNA from polyclonal populations of antibod 
ies may be amplified, fragmented if desired, ligated into 
pTX101 or a similar vector as described in U.S. Pat. No. 
5,348,867, incorporated herein by reference, and trans 
formed into an E. coli cell. The DNA may be introduced by 
electroporation, gene gun, etc. 
E. coli Surface displayed antibodies may be rapidly and 
efficiently Sorted using fluorescence activated cell Sorting 
techniques (FACS). 
Immunoassay Methods 
For the first time, a competitive immunoassay has been 
developed that takes advantage of anti-analyte binding anti 
bodies immobilized on a bacterial cell Surface. Several 
advantages of the disclosed immunoassay include generally 
the convenience, wide applicability and the simplicity, 
rapidity and Sensitivity of the assay. 
The present invention involves a novel method of carry 
ing out competitive immunoassays using antibodies attached 
to the Surface of cells. The disclosed immunoassays are 
useful for binding, purifying, removing, quantifying or 
otherwise generally detecting analytes. Antibodies 
expressed on bacterial cell Surfaces have been shown Sur 
prisingly adaptable for use in competitive immunoassay 
procedures. 
The immunoassay methods are carried out using antibod 
ies attached to the Surface of cells. One Selects an antibody 











detected, or what is referred to herein as the analyte. The 
analyte may be a medically relevant molecule, a marker 
molecule used in reactions, a pesticide or a toxic Species of 
interest. In order to conduct the assay, a Sample of the 
analyte is labeled, typically with a fluorescent moiety Such 
as fluorescein. Fluorescein may be covalently bound to an 
analyte Such as a protein using methods well known to the 
Synthetic chemist. A covalent conjugate with the analyte is 
formed. 
In a particular example, the analyte digoxin, a cardiac 
glycoside, was determined using fluorescein-digoxin conju 
gate. The assay was quantitative with a Sensitivity in the 
nanomolar range. 
The invention also provides methods of removing unde 
Sirable components from a given Sample, as exemplified by 
removing viral or other contaminants from blood Samples, 
removing environmental contaminants from water Samples, 
and the like. The cells expressing the antibody fragment on 
their Surface are contacted with the Sample, allowed to react 
and the cells removed by Simple centrifugation to obtain a 
purified Sample. 
Cells expressing an antibody fragment on their Surface 
may also be linked to a Solid Support, Such as in the form of 
beads, membrane or a column matrix, and the Sample 
Suspected of containing the unwanted antigenic component 
applied to the immobilized antibody. A purged or purified 
Sample is then obtained free from the unwanted antigen 
Simply by collecting the Sample from the column and 
leaving the antigen immunocomplexed to the immobilized 
antibody. 
Detection of immunocomplex formation is well known in 
the art and may be achieved through the application of 
numerous approaches. These approaches are typically based 
upon the detection of a label or marker, Such as any of the 
radioactive, fluore Scent, chemilumine Scent, 
electrochemiluminescent, biological or enzymatic tags or 
labels known in the art. U.S. Patents concerning the use of 
Such labels include U.S. Pat. Nos. 3,817,837; 3,850,752; 
3,939,350; 3,996.345; 4,277,437; 4,275,149 and 4,366,241, 
each incorporated herein by reference. Of course, one may 
find additional advantages through the use of a Secondary 
binding ligand Such as a Second antibody or a biotin/avidin 
ligand binding arrangement, as is known in the art. 
The first added component that becomes bound within the 
primary immune complexes may be detected by means of a 
Second binding ligand that has binding affinity for the 
Surface expressed antibody. In these cases, the Second bind 
ing ligand may be linked to a detectable label. The Second 
binding ligand is itself often an antibody, which may thus be 
termed a “secondary antibody. The primary immune com 
plexes are contacted with the labeled, Secondary binding 
ligand, or antibody, under conditions effective and for a 
period of time sufficient to allow the formation of secondary 
immune complexes. The Secondary immune complexes are 
then generally washed to remove any non-specifically bound 
labelled Secondary antibodies or ligands, and the remaining 
label in the Secondary immune complexes is then detected. 
Further methods include the detection of primary immune 
complexes by a two Step approach. A Second binding ligand, 
Such as an antibody, that has binding affinity for the Surface 
expressed antibody is used to form Secondary immune 
complexes, as described above. After Washing, the Second 
ary immune complexes are contacted with a third binding 
ligand or antibody that has binding affinity for the Second 
antibody, again under conditions effective and for a period of 
time Sufficient to allow the formation of immune complexes 
(tertiary immune complexes). The third ligand or antibody is 
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linked to a detectable label, allowing detection of the tertiary 
immune complexes thus formed. This System may provide 
for Signal amplification if this is desired. 
The immunoassay methods of the present invention have 
evident utility in the diagnosis of certain medical conditions 
Such as pregnancy where detection of a specific analyte is 
diagnostic of a medical condition. Here, a biological or 
clinical Sample Suspected of containing a Specific analyte is 
contacted with the Surface expressed antibody and detected 
according to any of the methods outline above. However, 
these embodiments also have applications to non-clinical 
Samples, Such as in the titering of analyte or antibody 
Samples, and in the Selection of hybridomas. 
In certain uses of the assay, cells containing antibodies on 
the Surface are produced as described previously. Antibodies 
known to bind tightly and Specifically to a molecule of 
interest are employed. The molecule could be a medically 
relevant molecule, a marker molecule used in a Scientific 
Study, a pesticide of environmental concern in groundwater, 
etc. A covalent conjugate of the molecule with a fluorescent 
moiety Such as fluorescein is Synthesized for use as a probe 
in binding. Other detection agents include radioactive 
compounds, enzyme conjugates, chemiluminescent reagents 
Such as luciferase and electrochemiluminescent reagents 
such as Ru(bpy)". (Yang et al., 1994; Blackburn et al., 
1991). The assay may also be carried out using tritium as the 
labeling agent for the antigen and performing a radioimmu 
noassay. The radioactivity may be detected using a Scintil 
lation counter to measure binding constants up to 10 or 
109M1. 
To perform the preferred assay, a known amount of the 
antibody-covered cells are placed in a Solution of a known 
concentration of the molecule-fluorescein conjugate along 
with an unknown concentration of the molecule. The 
molecule-fluorescein conjugate competes with free mol 
ecules in solution for binding to the antibody on the cell 
Surface. The higher the concentration of the molecule in the 
Solution, the fewer molecules of fluorescein-molecule con 
jugate will bind to the surface of the cells, while lower 
concentrations of the molecule will result in more of the 
conjugate bound to the cell Surface. 
Before measuring residual fluorescence, the cells are 
removed from the Solution, most conveniently by pelleting, 
and the fluorescence of the Supernatant measured. The assay 
is quantitative because the amount of observed fluorescence 
is proportional to the concentration of the molecule in the 
unknown Sample. If there is a very low concentration of the 
molecule to compete with the fluorescein conjugate, most of 
the conjugate will bind to the cells and will be removed from 
the Solution. The higher the concentration of the molecule in 
solution, the more molecules bind to the antibodies thereby 
preventing the conjugate from binding. In this case, more 
fluorescein conjugate remains in the Supernatant to give a 
Stronger fluorescent Signal. The assay can be calibrated to 
generate a quantitative measurement of the unknown con 
centration of the molecule. The entire assay takes less than 
an hour and requires only a basic fluorimeter. 
The cells with the antibody fragment displayed on their 
Surface may be attached to a Solid Support Such as a 
membrane, dipstick or beads to facilitate the removal of the 
antibody following reaction with antigen. 
Expression Library Selection Methods 
Vector Constructs 
The present invention involves the display of antibody 
molecules on the Surface of a bacteria. AS used herein, the 
term “antibody' or “antibody fragment” is used to refer to 











and IgE or any antibody-like molecule that has an antigen 
binding region, and includes antibody fragments Such as 
Fab', Fab, F(ab'), single domain antibodies (DABs), Fv, 
scFv (single chain Fv), and the like. The techniques for 
preparing and using various antibody-based constructs and 
fragments are well known in the art. 
Genes for recombinant antibodies or antibody fragments 
are first fused to the 3' of a Sequence that encodes a cell 
Surface targeting domain. The cell envelope of E. coli and 
other gram-negative bacteria consists of the inner membrane 
(cytoplasmic membrane), the peptidoglycan cell wall and 
the outer membrane. Although the latter normally Serves as 
a barrier to protein Secretion, a targeting Sequence has been 
developed that, when fused to normally Soluble proteins, can 
direct them to the cell surface (Francisco et al., 1992; 1993). 
The Surface targeting domain includes the first nine amino 
acids of Lipp, the major lipoprotein of E. coli fused to amino 
acid 46-159 of the Outer Membrane Protein A (OmpA). The 
function of the former is to direct the chimera to the outer 
membrane whereas the Omp A Sequence mediates the dis 
play of proteins at the C-terminal of Omp A. Lpp-Omp A 
(46-159) fusions have been used to anchor a variety of 
proteins Such as B-lactamase, a cellulose binding protein and 
alkaline phosphatase on the E. coli Surface. However, other 
analogous Surface targeting domains may be employed to 
Stably anchor the recombinant polypeptides on the cell 
Surface. 
Methods for the display of virtually any polypeptide on 
the Surface E. coli are described in U.S. Pat. No. 5,348,867 
issued Sep. 20, 1994, hereby incorporated by reference. Any 
library encoding a set of related polypeptide Sequences may 
be displayed on the Surface of E. coli. Examples of Such 
libraries include, libraries derived by mutagenesis of a 
homologous or heterologous protein, random peptide 
libraries, epitope libraries and libraries of recombinant anti 
body fragments, all of which may be created by methods 
known to those skilled in the art. 
Exemplary of the Surface expression method is an Lpp 
OmpA(46-159)-antibody fusion expressed in a gram 
negative bacterium. Due to the presence of the Lpp-Omp A 
(46-159) sequence, the fusion is localized on the outer 
membrane Such that the N-terminal domain is embedded in 
the bilayer and the antibody Sequence is fully exposed on the 
cell Surface. Recombinant antibodies expressed on the cell 
surface as Lpp-OmpA(46-159) fusions are functional and 
bind to antigens with high affinity. 
Antibody Fragment Constructs 
The specificity of an antibody is determined by the 
complementarity determining regions (CDRS) within the 
light chain variable regions (V) and heavy chain variable 
regions (V). The F., fragment of an antibody, which is 
about one-third the size of a complete antibody contains the 
heavy and light chain variable regions, the complete light 
chain constant region and a portion of the heavy chain 
constant region. F, molecules are stable and asSociate well 
due to the contribution of the constant region Sequences. 
However, the yield of functional F expressed in bacterial 
systems is lower than that of the smaller F fragment which 
contains only the variable regions of the heavy and light 
chains. The F fragment is the Smallest portion of an 
antibody that Still retains a functional antigen binding site. 
The F fragment has the Same binding properties as the F., 
however without the stability conferred by the constant 
regions, the two chains of the F can dissociate relatively 
easily in dilute conditions. 
To overcome this problem, V and V, regions may be 
fused via a polypeptide linker (Huston et al., 1991) to 
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Stabilize the antigen binding site. This single polypeptide F. 
fragment is known as a single chain antibody (ScP). The V, 
and V, can be arranged with either domain first. The linker 
joins the carboxy terminus of the first chain to the amino 
terminus of the Second chain. 
While the present invention has been illustrated with 
display of Single chain F molecules on the Surface of the 
bacteria, one of skill in the art will recognize that heavy or 
light chain F or F, fragments may also be used with this 
System. A heavy or light chain can be displayed on the 
surface followed by the addition of the complementary chain 
to the Solution. The two chains are then allowed to combine 
on the surface of the bacteria to form a functional antibody 
fragment. Addition of random non-specific light or heavy 
chain Sequences allows for the production of a combinatorial 
System to generate a library of diverse members. 
Antibody Fragment Gene Isolation 
To accomplish construction of antibody fragments the 
encoding genes are isolated and then modified to permit 
cloning into the expression vector. Although methods can be 
used such as probing the DNA for V and V, from hybri 
doma cDNA (Maniatis et al., 1982) or constructing a syn 
thetic gene for V and V, (Barbas et al., 1992), a 
convenient, mode is to use template directed methods to 
amplify the antibody Sequences. A diverse population of 
antibody genes can be amplified from a template Sample by 
designing primers to the conserved Sequences at the 3' and 
5' ends of the variable region known as the framework or to 
the constant regions of the antibody (Iverson et al., 1989). 
Within the primers, restriction sites can be placed to facili 
tate cloning into an expression vector. By directing the 
primers to these conserved regions, the diversity of the 
antibody population is maintained to allow for the construc 
tion of diverse libraries. The Specific Species and class of 
antibody can be defined by the selection of the primer 
Sequences as illustrated by the large number of Sequences for 
all types of antibodies given in Kabat et al., 1987, hereby 
incorporated by reference. 
Messenger RNA isolated from the spleen or peripheral 
blood of an animal can be used as the template for the 
amplification of an antibody library. In certain 
circumstances, where it is desirable to display a homoge 
neous population of antibody fragments on the cell Surface, 
mRNA may be isolated from a population of monoclonal 
antibodies. Messenger RNA from either source can be 
prepared by Standard methods and used directly or for the 
preparation of a cDNA template. 
Generation of mRNA for cloning antibody purposes is 
readily accomplished by following the well-known proce 
dures for preparation and characterization of antibodies (see, 
e.g., Antibodies: A Laboratory Manual, 1988; incorporated 
herein by reference). 
Generation of monoclonal antibodies (MAbs) follows 
generally the same procedures as those for preparing poly 
clonal antibodies. Briefly, a polyclonal antibody is prepared 
by immunizing an animal with an immunogenic composi 
tion in accordance and collecting antisera from that immu 
nized animal. A wide range of animal Species can be used for 
the production of antisera. Typically the animal used for 
production of anti-antisera is a rabbit, a mouse, a rat, a 
hamster, a guinea pig or a goat. Because of the relatively 
large blood volume of rabbits, rabbits are usually preferred 
for production of polyclonal antibodies. 
Immunogenic compositions often vary in immunogenic 
ity. It is often necessary therefore to boost the host immune 
System, as may be achieved by coupling a peptide or 











ferred carriers are keyhole limpet hemocyanin (KLH) and 
bovine serum albumin (BSA). Other albumins such as 
ovalbumin, mouse Serum albumin or rabbit Serum albumin 
can also be used as carriers. Recognized means for conju 
gating a polypeptide to a carrier protein are well known and 
include glutaraldehyde, m-male imidobenzoyl-N- 
hydroxySuccinimide ester, carbodiimides and bis-diazotized 
benzidine. 
The immunogenicity of a particular immunogen compo 
Sition may be enhanced by the use of non-specific Stimula 
tors of the immune response, known as adjuvants. Exem 
plary and preferred adjuvants include complete Freund's 
adjuvant (a non-specific stimulator of the immune response 
containing killed Mycobacterium tuberculosis), incomplete 
Freund's adjuvants and aluminum hydroxide adjuvant. 
The amount of immunogen composition used in the 
production of polyclonal antibodies varies upon the nature 
of the immunogen as well as the animal used for immuni 
Zation. A variety of routes can be used to administer the 
immunogen (Subcutaneous, intramuscular, intradermal, 
intravenous and intraperitoneal). The production of poly 
clonal antibodies may be monitored by Sampling blood of 
the immunized animal at various points following immuni 
Zation. A Second, booster injection, may also be given. The 
process of boosting and titering is repeated until a Suitable 
titer is achieved. When a desired level of immunogenicity is 
obtained, the immunized animal can be bled and the Serum 
isolated, Stored and the Spleen harvested for the isolation of 
mRNA from the polyclonal response or the animal can be 
used to generate MAbs for the isolation of mRNA from a 
homogeneous antibody population. 
MAbs may be readily prepared through use of well 
known techniques, Such as those exemplified in U.S. Pat. 
No. 4,196,265, incorporated herein by reference. Typically, 
this technique involves immunizing a Suitable animal with a 
Selected immunogen composition, e.g. a Small molecule 
hapten conjugated to a carrier, a purified or partially purified 
protein, polypeptide or peptide. The immunizing composi 
tion is administered in a manner effective to Stimulate 
antibody producing cells. Rodents Such as mice and rats are 
frequently used animals; however, the use of rabbit, sheep 
frog cells is also possible. The use of rats may provide 
certain advantages (Goding, pp. 60–61, 1986), but mice are 
preferred, particularly the BALB/c mouse as this is most 
routinely used and generally gives a higher percentage of 
Stable fusions. 
Following immunization, Somatic cells with the potential 
for producing antibodies, specifically B lymphocytes (B 
cells), are selected for use in the MAb generating protocol. 
These cells may be obtained from biopsied Spleens, tonsils 
or lymph nodes, or from blood Samples. Spleen cells and 
blood cells are preferable, the former because they are a rich 
Source of antibody-producing cells that are in the dividing 
plasmablast Stage, and the latter because blood is easily 
accessible. Often, a panel of animals will have been immu 
nized and the Spleen of animal with the highest antibody titer 
will be removed and the spleen lymphocytes obtained by 
homogenizing the Spleen with a Syringe. Typically, a spleen 
from an immunized mouse contains approximately 5x10" to 
2x10 lymphocytes. 
The antibody-producing B lymphocytes from the immu 
nized animal are then fused with cells of an immortal 
myeloma cell, generally one of the same Species as the 
animal that was immunized. Myeloma cell lines Suited for 
use in hybridoma-producing fusion procedures preferably 
are non-antibody-producing, have high fusion efficiency, 
and enzyme deficiencies that render then incapable of grow 
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ing in certain Selective media which Support the growth of 
only the desired fused cells (hybridomas). 
Any one of a number of myeloma cells may be used, as 
are known to those of skill in the art (Goding, pp. 65-66, 
1986; Campbell, 1984). For example, where the immunized 
animal is a mouse, one may use P3-X63/Ag8, X63-Ag8.653, 
NS1/1Ag41, Sp210-Ag14, FO, NSO/U, MPC-11, MPC11 
X45-GTG 1.7 and S194/5XX0 Bul; for rats, one may use 
R210. RCY3, Y3-Ag 1.2.3, IR983F and 4B210; and U-266, 
GM1500-GRG2, LICR-LON-HMy2 and UC729-6 are all 
useful in connection with human cell fusions. 
One preferred murine myeloma cell is the NS-1 myeloma 
cell line (also termed P3-NS-1-Ag4-1), which is readily 
available from the NIGMS Human Genetic Mutant Cell 
Repository by requesting cell line repository number 
GM3573. Another mouse myeloma cell line that may be 
used is the 8-azaguanine-resistant mouse murine myeloma 
SP2/0 non-producer cell line. 
Methods for generating hybrids of antibody-producing 
Spleen or lymph node cells and myeloma cells usually 
comprise mixing Somatic cells with myeloma cells in a 2:1 
proportion, though the proportion may vary from about 20:1 
to about 1:1, respectively, in the presence of an agent or 
agents (chemical or electrical) that promote the fusion of cell 
membranes. Fusion methods using Sendai virus have been 
described by Kohler & Milstein (1975; 1976), and those 
using polyethylene glycol (PEG), such as 37% (v/v) PEG, 
by Gefter et al., 1977). The use of electrically induced fusion 
methods is also appropriate (Goding pp. 71-74, 1986). 
Fusion procedures usually produce viable hybrids at low 
frequencies, about 1x10 to 1x10. However, this does not 
pose a problem, as the viable, fused hybrids are differenti 
ated from the parental, unfused cells (particularly the 
unfused myeloma cells that would normally continue to 
divide indefinitely) by culturing in a selective medium. The 
Selective medium is generally one that contains an agent that 
blocks the de novo Synthesis of nucleotides in the tissue 
culture media. Exemplary and preferred agents are 
aminopterin, methotrexate, and azaserine. Aminopterin and 
methotrexate block de novo Synthesis of both purines and 
pyrimidines, whereas azaserine blocks only purine Synthe 
Sis. Where aminopterin or methotrexate is used, the media is 
Supplemented with hypoxanthine and thymidine as a Source 
of nucleotides (HAT medium). Where azaserine is used, the 
media is Supplemented with hypoxanthine. 
The preferred selection medium is HAT. Only cells 
capable of operating nucleotide Salvage pathways are able to 
survive in HAT medium. The myeloma cells are defective in 
key enzymes of the Salvage pathway, e.g., hypoxanthine 
phosphoribosyl transferase (HPRT), and they cannot sur 
vive. The B cells can operate this pathway, but they have a 
limited life Span in culture and generally die within about 
two weeks. Therefore, the only cells that can survive in the 
Selective media are those hybrids formed from myeloma and 
B cells. 
This culturing provides a population of hybridomas from 
which Specific hybridomas are Selected. Typically, Selection 
of hybridomas is performed by culturing the cells by Single 
clone dilution in microtiter plates, followed by testing the 
individual clonal Supernatants (after about two to three 
weeks) for the desired reactivity. Simple and rapid assays 
include radioimmunoassays, enzyme immunoassays, cyto 
toxicity assays, plaque assays, dot immunobinding assays, 
and the like. 
The selected hybridomas are serially diluted and cloned 
into individual antibody-producing cell lines from which 











The cell lines may be exploited for MAb production in two 
basic ways. A Sample of the hybridoma can be injected 
(often into the peritoneal cavity) into a histocompatible 
animal of the type that was used to provide the Somatic and 
myeloma cells for the original fusion. The injected animal 
develops tumors Secreting the Specific monoclonal antibody 
produced by the fused cell hybrid. The body fluids of the 
animal, Such as Serum or ascites fluid, can then be tapped to 
provide MAbs in high concentration. The individual cell 
lines could also be cultured in vitro, where the MAbs are 
naturally secreted into the culture medium from which they 
can be readily obtained in high concentrations. MAbs pro 
duced by either means may be further purified, if desired, 
using filtration, centrifugation and various chromatographic 
methods such as HPLC or affinity chromatography. 
Following the isolation and characterization of the desired 
monoclonal antibody, the mRNA can be isolated using 
techniques well known in the art and used as a template for 
amplification of the target Sequence. 
Amplification of Antibody Gene Fragments 
A number of template dependent processes are available 
to amplify the target Sequences present in a given template 
Sample. One of the best known amplification methods is the 
polymerase chain reaction (referred to as PCR) which is 
described in detail in U.S. Pats. Nos. 4,683,195, 4,683,202 
and 4,800,159, and in Innis et al. (1990), each of which is 
incorporated herein by reference in its entirety. Briefly, in 
PCR, two primer Sequences are prepared which are comple 
mentary to regions on opposite complementary Strands of 
the target Sequence. An excess of deoxynucleoside triphos 
phates are added to a reaction mixture along with a DNA 
polymerase, e.g., Taq polymerase. If the target Sequence is 
present in a sample, the primers will bind to the target and 
the polymerase will cause the primers to be extended along 
the target Sequence by adding on nucleotides. By raising and 
lowering the temperature of the reaction mixture, the 
extended primers will dissociate from the target to form 
reaction products, exceSS primers will bind to the target and 
to the reaction products and the proceSS is repeated. Pref 
erably a reverse transcriptase PCR amplification procedure 
may be performed in order to quantify the amount of target 
amplified. Polymerase chain reaction methodologies are 
well known in the art. 
Another method for amplification is the ligase chain 
reaction (“LCR”), disclosed in EPA No. 320 308, incorpo 
rated herein by reference in its entirety. In LCR, two 
complementary probe pairs are prepared, and in the presence 
of the target Sequence, each pair will bind to opposite 
complementary Strands of the target Such that they abut. In 
the presence of a ligase, the two probe pairs will link to form 
a Single unit. By temperature cycling, as in PCR, bound 
ligated units dissociate from the target and then Serve as 
“target Sequences” for ligation of exceSS probe pairs. U.S. 
Pat. No. 4,883,750 describes a method similar to LCR for 
binding probe pairs to a target Sequence. 
Qbeta Replicase, described in PCT Application No. PCT/ 
US87/00880, may also be used as an amplification method. 
In this method, a replicative sequence of RNA which has a 
region complementary to that of a target is added to a Sample 
in the presence of an RNA polymerase. The polymerase will 
copy the replicative Sequence which can then be detected. 
An isothermal amplification method, in which restriction 
endonucleases and ligases are used to achieve the amplifi 
cation of target molecules that contain nucleotide 5'-alpha 
thio-triphosphates in one Strand of a restriction site may 
also be useful in the amplification of nucleic acids (Walker 
et al., 1992). 
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Strand Displacement Amplification (SDA) is another 
method of carrying out isothermal amplification of nucleic 
acids which involves multiple rounds of Strand displacement 
and Synthesis, i.e., nick translation. A similar method, called 
Repair Chain Reaction (RCR) involves annealing several 
probes throughout a region targeted for amplification, fol 
lowed by a repair reaction in which only two of the four 
bases are present. The other two bases can be added as 
biotinylated derivatives for easy detection. A similar 
approach is used in SDA. Target Specific Sequences can also 
be detected using a cyclic probe reaction (CPR). In CPR, a 
probe having a 3' and 5' Sequences of non-specific DNA and 
middle sequence of specific RNA is hybridized to DNA 
which is present in a Sample. Upon hybridization, the 
reaction is treated with RNaseH, and the products of the 
probe identified as distinctive products which are released 
after digestion. The original template is annealed to another 
cycling probe and the reaction is repeated. 
Other amplification methods are described in GB Appli 
cation No. 2 202 328, and in PCT Application No. PCT/ 
US89/01025, each of which is incorporated herein by ref 
erence in its entirety, may be used in accordance with the 
present invention. In the former application, "modified’ 
primers are used in a PCR like, template and enzyme 
dependent synthesis. The primers may be modified by 
labelling with a capture moiety (e.g., biotin) and/or a detec 
tor moiety (e.g., enzyme). In the latter application, an excess 
of labeled probes is added to a Sample. In the presence of the 
target Sequence, the probe binds and is cleaved catalytically. 
After cleavage, the target Sequence is released intact to be 
bound by excess probe. Cleavage of the labelled probe 
Signals the presence of the target Sequence. 
Other nucleic acid amplification procedures include 
transcription-based amplification Systems (TAS), including 
nucleic acid Sequence based amplification (NASBA) and 
3SR (Kwoh et al., 1989). In NASBA, the nucleic acids can 
be prepared for amplification by Standard phenol/chloroform 
extraction, heat denaturation of a clinical Sample, treatment 
with lysis buffer and minispin columns for isolation of DNA 
and RNA or guanidinium chloride extraction of RNA. These 
amplification techniques involve annealing a primer which 
has target Specific Sequences. Following polymerization, 
DNA/RNA hybrids are digested with RNase H while double 
Stranded DNA molecules are heat denatured again. In either 
case the single stranded DNA is made fully double stranded 
by addition of Second target specific primer, followed by 
polymerization. The double stranded DNA molecules are 
then multiply transcribed by a polymerase such as T7 or 
SP6. In an isothermal cyclic reaction, the RNAS are reverse 
transcribed into double stranded DNA, and transcribed once 
against with a polymerase such as T7 or SP6. The resulting 
products, whether truncated or complete, indicate target 
Specific Sequences. 
Davey et al., EPA No. 329 822 (incorporated herein by 
reference in its entirety) disclose a nucleic acid amplification 
proceSS involving cyclically Synthesizing Single-Stranded 
RNA (“ssRNA”), ssDNA, and double-stranded DNA 
(dsDNA), which may be used in accordance with the present 
invention. The ssRNA is a first template for a first primer 
oligonucleotide, which is elongated by reverse transcriptase 
(RNA-dependent DNA polymerase). The RNA is then 
removed from the resulting DNA:RNA duplex by the action 
of ribonuclease H (RNase H, an RNase specific for RNA in 
duplex with either DNA or RNA). The resultant ssDNA is a 
Second template for a Second primer, which also includes the 
Sequences of an RNA polymerase promoter (exemplified by 











This primer is then extended by DNA polymerase 
(exemplified by the large “Klenow” fragment of E. coli 
DNA polymerase I), resulting as a double-stranded DNA 
(“dsDNA) molecule, having a sequence identical to that of 
the original RNA between the primers and having 
additionally, at one end, a promoter Sequence. This promoter 
Sequence can be used by the appropriate RNA polymerase to 
make many RNA copies of the DNA. These copies can then 
re-enter the cycle leading to very Swift amplification. With 
proper choice of enzymes, this amplification can be done 
isothermally without addition of enzymes at each cycle. 
Because of the cyclical nature of this process, the Starting 
sequence can be chosen to be in the form of either DNA or 
RNA. 
Miller et al., PCT Application WO 89/06700 
(incorporated herein by reference in its entirety) disclose a 
nucleic acid Sequence amplification Scheme based on the 
hybridization of a promoter/primer Sequence to a target 
single-stranded DNA (“ssDNA) followed by transcription 
of many RNA copies of the Sequence. This Scheme is not 
cyclic, i.e., new templates are not produced from the result 
ant RNA transcripts. Other amplification methods include 
“race” and “one-sided PCR" (Frohman, 1990; O'Hara et al., 
1989). 
Methods based on ligation of two (or more) oligonucle 
otides in the presence of nucleic acid having the Sequence of 
the resulting “di-oligonucleotide', thereby amplifying the 
di-oligonucleotide, may also be used in the amplification 
step (Wu et al., 1989). 
Amplification products may be analyzed by agarose, 
agarose-acrylamide or polyacrylamide gel electrophoresis 
using standard methods (see, e.g., Maniatis et al. 1982). For 
example, one may use a 1% agarose gel Stained With 
ethidium bromide and visualized under UV light. 
Alternatively, the amplification products may be integrally 
labeled with radio- or fluorometrically-labeled nucleotides. 
Gels can then be exposed to X-ray film or visualized under 
the appropriate Stimulating spectra, respectively. 
Semisynthetic Antibody Gene Fragments and Preparation of 
Mutants 
Genes for antibody fragments may also be generated by 
Semisynthetic methods known in the art (Barbas et al., 
1992). Using the conserved regions of an antibody fragment 
as a framework, variable regions can be inserted in random 
combinations one or more at a time to alter the Specificity of 
the antibody fragment and generate novel binding sites, 
especially in the generation of antibodies to antigens not 
conducive to immunization Such as toxic or labile com 
pounds. Along the same lines a known antibody Sequence 
may be varied by introducing mutations randomly or site 
specifically. This may be accomplished by methods well 
known in the art Such as mutagenesis with mismatched 
primers or error-prone PCR (Innir, 1990). 
Functionally Equivalent Amino Acids 
AS previously discussed, modification and changes may 
be made in the Structures of the Signal or transversing 
proteins and peptides and Still obtain a molecule having like, 
or otherwise desirable, characteristics. For example, certain 
amino acids may be Substituted for other amino acids in a 
protein Structure without appreciable loSS of functional 
activity to transport the antibody, antibody fragment or 
peptide to the cell Surface. Since it is the interactive capacity 
and nature of a protein that defines that protein's biological 
functional activity, certain amino acid Sequence Substitu 
tions can be made in a protein sequence (or, of course, its 
underlying DNA coding sequence) and nevertheless obtain 
a protein with like (agonistic) properties. Equally, the same 
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considerations may be employed to create a protein or 
polypeptide with countervailing (e.g., antagonistic) proper 
ties. It is thus contemplated by the inventors that various 
changes may be made in the Sequences of the target and 
transversing proteins (or underlying DNA) without appre 
ciable loss of their biological utility or activity. 
It is also well understood by the skilled artisan that, 
inherent in the definition of a biologically functional equiva 
lent protein or peptide, is the concept that there is a limit to 
the number of changes that may be made within a defined 
portion of the molecule and Still result in a molecule with an 
acceptable level of equivalent biological activity. Biologi 
cally functional equivalent peptides are thus defined herein 
as those peptides in which certain, not most or all, of the 
amino acids may be Substituted. Of course, a plurality of 
distinct proteins/peptides with different Substitutions may 
easily be made and used in accordance with the invention. 
It is also well understood that where certain residues are 
shown to be particularly important to the biological or 
Structural properties of a protein or peptide, Such residues 
may not generally be exchanged. 
Amino acid Substitutions are generally based on the 
relative similarity of the amino acid Side-chain Substituents, 
for example, their hydrophobicity, hydrophilicity, charge, 
size, and the like. An analysis of the size, shape and type of 
the amino acid Side-chain Substituents reveals that arginine, 
lysine and histidine are all positively charged residues; that 
alanine, glycine and Serine are all a similar size; and that 
phenylalanine, tryptophan and tyrosine all have a generally 
Similar shape. Therefore, based upon these considerations, 
arginine, lysine and histidine, alanine, glycine and Serine; 
and phenylalanine, tryptophan and tyrosine, are defined 
herein as biologically functional equivalents. 
To effect more quantitative changes, the hydropathic 
index of amino acids may be considered. Each amino acid 
has been assigned a hydropathic indeX on the basis of their 
hydrophobicity and charge characteristics, these are: isoleu 
cine (+4.5); Valine (+4.2); leucine (+3.8); phenylalanine 
(+2.8); cysteine/cystine (+2.5); methionine (+1.9); alanine 
(+1.8); glycine (-0.4); threonine (-0.7); Serine (-0.8); tryp 
tophan (-0.9); tyrosine (-1.3); proline (-1.6); histidine 
(-3.2); glutamate (-3.5); glutamine (-3.5); aspartate (-3.5); 
asparagine (-3.5); lysine (-3.9); and arginine (-4.5). 
The importance of the hydropathic amino acid indeX in 
conferring interactive biological function on a protein is 
generally understood in the art (Kyte & Doolittle, 1982, 
incorporated herein by reference). It is known that certain 
amino acids may be Substituted for other amino acids having 
a similar hydropathic indeX or Score and Still retain a similar 
biological activity. In making changes based upon the hydro 
pathic index, the Substitution of amino acids whose hydro 
pathic indices are within +2 is preferred, those which are 
within +1 are particularly preferred, and those within +0.5 
are even more particularly preferred. 
It is also understood in the art that the Substitution of like 
amino acids can be made effectively on the basis of 
hydrophilicity, particularly where the biological functional 
equivalent protein or peptide thereby created is intended for 
use in immunological embodiments, as in the present case. 
U.S. Pat. No. 4,554,101, incorporated herein by reference, 
States that the greatest local average hydrophilicity of a 
protein, as governed by the hydrophilicity of its adjacent 
amino acids, correlates with its immunogenicity and 
antigenicity, i.e. with a biological property of the protein. 
As detailed in U.S. Pat. No. 4,554,101, the following 
hydrophilicity values have been assigned to amino acid 











glutamate (+3.0t1); Serine (+0.3); asparagine (+0.2); 
glutamine (+0.2); glycine (O); threonine (-0.4); proline 
(-0.5+1); alanine (-0.5); histidine (-0.5); cysteine (-1.0); 
methionine (-1.3); Valine (-1.5); leucine (-1.8); isoleucine 
(-1.8); tyrosine (-2.3); phenylalanine (-2.5); tryptophan 
(-3.4). 
In making changes based upon Similar hydrophilicity 
values, the Substitution of amino acids whose hydrophilicity 
values are within +2 is preferred, those which are within +1 
are particularly preferred, and those within t0.5 are even 
more particularly preferred. 
While discussion has focused on functionally equivalent 
polypeptides arising from amino acid changes, it will be 
appreciated that these changes may be effected by alteration 
of the encoding DNA, taking into consideration also that the 
genetic code is degenerate and that two or more codons may 
code for the same amino acid, as shown in Table 1. 
TABLE 1. 
Amino Acids Codons 
Alanine Ala A. GCA GCC GCG GCU 
Cysteine Cys C UGC UGU 
Aspartic Asp D GAC GAU 
acid 
Glutamic Glu E GAA GAG 
acid 
Phenyl- Phe F UUC UUU 
alanine 
Glycine Gly G GGA GGC GGG GGU 
Histidine His H CAC CAU 
Isoleucine Ile I AUA AUC AUU 
Lysine Lys K AAA AAG 
Leucine Leu L UUA UUG CUA CUC CUG CUU 
Methionine Met M AUG 
Asparagine Asn N AAC AAU 
Proline Pro P CCA CCC CCG CCU 
Glutamine Glin O CAA CAG 
Arginine Arg R AGA AGG CGA CGC CGG CGU 
Serine Ser S AGC AGU UCA UCC UCG UCU 
Threonine Thr T ACA ACC ACG ACU 
Valine Val V GUA GUC GUG GUU 
Tryptophan Trp W UGG 
Tyrosine Tyr Y UAC UAU 
Materials and Methods 
Bacterial Strains, Plasmids, and Growth Conditions 
E. coli strain JM109 end A1 recA1 gyra thi-1 hsdR17 
(r-, m--) relA1 supE44A(lac-proAB)/F" traD36 proAB 
lacI lacZAM15 was used for all studies. p.TX101 codes for 
an Lpp-OmpA-f-lactamase fusion (Francisco et al., 1992). 
pTX152 codes for an Lpp-Omp A-Scr(digoxin) fusion, 
where the ScF(digoxin) is an anti-digoxin Single chain F, 
consisting of the heavy- and light-chain variable regions (V, 
and V.). The V and V., joined by a 15 amino acid 
(Gly) Ser linker (Huston et al., 1988), were amplified 
from messenger RNA isolated from two separate anti 
digoxin hybridomas. An 11 amino acid peptide from the 
Herpes Simplex Virus glycoprotein (Novagen) was intro 
duced at the C-terminus of the Sclf for analytical purposes. 
pTX152 was constructed by first removing the bla from 
pTX101 by digestion with EcoRI and BamHI. The amplified 
gene coding for the anti-digoxin ScF was then digested with 
EcoRI and BamHI and ligated into pTX101. Both pTX101 
and pTX152 carried the chloramphenicol resistance gene. 
Cultures were grown in LB medium (Difco) supple 
mented with 0.2% glucose and chloramphenicol (50 ug/ml) 
at a temperature of either 24 C. or 37 C. 
ELISA 
Overnight cultures grown at 24 C. were harvested, 
resuspended in PBS at ODoo=2.0 and lysed by passage 
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through a French pressure cell at 20,000 psi. The lysates 
were then diluted with 1 volume of phosphate buffered 
saline containing 2.0% bovine serum albumin (PBS/2% 
BSA) and 5 mM of the protease inhibitor phenylmethylsul 
fonyl fluoride (PMSF).96 well microtiter plates were incu 
bated overnight at 37 C. with 100 ul of 100 lug/ml of either 
bovine serum albumin (BAS) or digoxin-conjugated BSA 
(digoxin-BSA) in 0.1M sodium carbonate buffer (pH 9.2). 
All Subsequent Steps were carried out at room temperature. 
The wells were fixed for 5 min with 100 ul methanol and 
were then blocked for 45 min with 200ul of pBS/1% BSA. 
After removing the blocking Solution, the Wells were incu 
bated for 2 hr with 100 ul of lysates, washed 3 times with 
200ul PBS/0.1% Tween 20 and incubated for 1 hr with 100 
til/well of monoclonal antibodies against the HSV peptide or 
antiserum against B-lactamase. The Wells were again washed 
3 times with PBS/0.1% Tween, incubated for 1 hr with 100 
All of the appropriate Secondary antibodies conjugated with 
horseradish peroxidase and were finally washed 5 times with 
PBS/O.1% Tween and 2 times with PBS. After addition of 
the substrate 2,2'-azino-bis(3-ethylbenzthiazoline-6-sulfonic 
acid) (Pierce, Rockford, Ill.) the absorbance of each well 
was measured at 410 nm. 
Whole cell ELISAS were performed as described above 
except that 100 ul Samples of overnight cultures that had 
been resuspended in PBS/1 BSA at OD=1.0 were used 
instead of cell lysates. 
Fluorescence Microscopy and Fluorescence Activated Cell 
Sorting (FACS) 
For fluorescence microScopy, overnight cultures grown at 
24 C. were harvested, resuspended at OD=0.5 in PBS 
containing 107M fluorescein-conjugated digoxin (digoxin 
FITC; ILS LTD, London) and were incubated at room 
temperature for 1 hr. Prior to microscopy the cells were 
washed once with PBS and resuspended in equal volumes of 
PBS and Vectashield mounting medium (Vector 
Laboratories) at an ODoo of approximately 2.0. 
Protein Measurements 
The protein composition of whole cell membrane frac 
tions isolated from overnight cultures was analyzed by 
SDS-PAGE on 12% acrylamide gels and by Western blotting 
using anti-HSV monoclonal antibodies obtained from 
Novagen Inc. (Madison, Wis.), and anti-OmpA antiserum. 
Whole membrane fractions were prepared as described in 
Francisco et al. (1992). 
The following Examples are intended to illustrate the 
practice of the present invention and are not intended to be 
limiting. Although the invention is here demonstrated with 
a particular Single chain antibody on the Surface of E. coli, 
other forms of antibody molecules Such as an F, or F. 
could be used. Nor is the method limited to expression on an 
E. coli cell Surface as it is contemplated that other host cells 
may also be used as numerous other gram negative organ 
SS. 
EXAMPLE 1. 
Surface Expression of Anti-digoxin Single Chain Fv Anti 
bodies 
A Single chain F. Specific for digoxin was constructed by 
PCR amplification of the V and V, joined by a 15 amino 
acid (Gly) Serl linker (Huston et al., 1989)760. A 33 
residue sequence encoding an 11 amino acid peptide from 
the Herpes Simplex Virus glycoprotein (Novagen) was 
introduced at the C-terminus of the scF for analytical 
purposes. The presence of the HSV peptide allowed detec 
tion of the ScF(digoxin) protein by reaction with a mono 











Sequence of the Single chain F antibody fragment is dis 
closed in FIG. 1 (SEQ ID NO: 1). 
The gene encoding the ScF(digoxin) antibody was ligated 
in frame to lpp-ompA(46-159) from plasmid pTX101 
(Francisco et al., 1992), as follows: First, the bla from 
plasmid pTX101, which encodes an Lpp-OmpA(46-159)- 
B-lactamase fusion was excised by digestion with EcoRI and 
BamHI. The amplified gene coding for the ScF(digoxin) 
was then digested with EcoRI and BamHI and ligated into 
pTX101. The resulting plasmid designated pTX152 was 
identical to pTX101 except that the bla gene of pTX101 was 
substituted with the scE,(digoxin) fragment. Both pTX101 
and pTX152 carry the chloramphenicol resistance gene for 
antibiotic Selection of transformants. 
E. coli JM109 was transformed with pTX152 and trans 
formants were Selected on plates containing chlorampheni 
col. Using a single transformant colony, the presence of the 
Lpp-OmpA(46-159)-scF(digoxin) fusion was confirmed 
by restriction analysis and DNA sequencing. 
Cells were grown in liquid culture at 37 C. and used to 
isolate total membranes. The presence of a band of the 
expected size (42 kDa) was detected in Western blots of 
whole cell membranes probed with antibodies specific for 
Omp A and for the HSV peptide (FIG. 2A). Cells containing 
pTX152 produced a protein which reacted with both the 
HSV-specific and the Omp A Specific Sera, as expected for 
the Lpp-Omp A-Scr(digoxin) fusion. Control cells contain 
ing pTX101 reacted only with Omp A antiserum. The lower 
molecular weight band in lanes 1 and 2 corresponds to the 
intact Omp A protein of E. coli. 
The near absence of lower molecular weight bands croSS 
reacting with either the anti-HSV or the anti-Omp A anti 
bodies indicated that the ScF(digoxin) was not Subjected to 
proteolysis ostensibly because it was anchored on the cell 
Surface and consequently is physically Separated from intra 
cellular proteases. The intensity of the Lpp-OmpA(46-159) 
-scF(digoxin) band in FIG. 2A is comparable to that of the 
native OmpAband. The latter is a highly expressed protein 
that is present in the E. coli outer membrane at about 
100,000 copies per cell (Lugtenberg & Van Alphen, 1983). 
The level of expression Lpp-OmpA(46-159)-scF(digoxin) 
is on the order of 50,000-100,000 copies per cell. 
EXAMPLE 2 
This Example describes the Surface display and Screening 
of antibody libraries generated by PCR amplification of 
mRNA from spleen cells of mammals immunized with the 
desired antigen. The Example describes how the display of 
recombinant antibody libraries on the cell surface and the 
Screening of Such libraries by fluorescently activated cell 
Sorting can be used to identify clones that bind to the desired 
antigen with high affinity and thus constitutes and in Vitro 
replacement of hybridoma technology. 
Construction and Screening of an Ab library generated by 
PCR amplification of spleen mRNA 
Balb/c mice were immunized with digoxin using Standard 
protocols (Harlow & Lane, 1988). After at least two booster 
injections, antiserum was collected and the titer of the 
antibody response towards digoxin was determined by 
ELISA assayS. Mice exhibiting high anti-digoxin titers were 
Sacrificed and the intact Spleens were removed and used to 
extract mRNA (Sastry et al., 1989). The spleen mRNA was 
Subsequently used as template for PCR amplification using 
primers complementary to constant and variable domain 
framework regions of different antibody Subclasses. 
Separate rounds of PCR amplification were employed to 
amplify V and V, Sequences. PCR products of the expected 
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molecular weight were purified following electrophoresis on 
agarose gels, digested with Scal and ligated to give a gene 
encoding a full length gene encoding the Sequence V 
(Gly)-Ser-V,-(HSV tag). Subsequently, the ligated DNA 
was treated with EcoRI and BamHI and was ligated to the 
large EcoRI-BamHI fragment of pTX101. The resulting 
DNA was used to transform DH10b cells by electroporation. 
The electroporation mixture was used to inoculate Shake 
flasks with LB media containing chloramphenicol. After 
growth for several generations at 24 C. the cells were 
harvested by centrifugation and used for fluorescently acti 
Vated cell Sorting. 
Enrichment of cells displaying scF(digoxin) by FACS 
Antibody expressing cells were Sorted essentially quan 
titatively from a moderate excess of control E. coli in a 
Single Step. Specifically, in mixtures containing JM109/ 
pTX101 control cells at an excess of either 100:1 or 1,000:1, 
the fraction of the total population that was Sorted in the high 
fluorescence intensity window was 1.1% and 0.1% respec 
tively (after Subtracting the background), as expected from 
the ratio of input cells. 
The use of FACS for isolating rare clones from a very 
large excess of background was evaluated. JM109/pTX101 
and JM101/pTX152 were mixed at a ratio of 100,000:1 and 
labeled with digoxin-FITC. Following washing to remove 
any non-specific binding of the digoxin-fluorescein conju 
gate on the control E. coli, 500,000 cells were run through 
the FACSort flow cytometer. A wide Sorting gate, i.e., the 
minimum fluorescence required for acceptance of an indi 
vidual cell, was selected such that up to 0.2% of the control 
cells fell within the sorting window. This ensured that all the 
ScF(digoxin) expressing cells would be recovered. The cells 
having an allowable fluorescence signal were collected and 
grown in fresh media at 37 C. 
An aliquot from that culture was used to inoculate fresh 
media and incubated at 24 C. Cells grown at this lower 
temperature were used for FACS because of the higher 
extent of Surface display of the ScF(digoxin) antibody on 
the surface of cells grown at 24 C. 500,000 cells from this 
culture were run again through the FACSort and those with 
a fluorescence within the allowable window were collected 
automatically under Sterile conditions. The Sorted popula 
tion was grown first at 37 C. and then subcultures at 24 C. 
and was Subjected to a final round of Sorting as above. 
To ensure the complete absence of artifacts due to non 
specific cell adhesion in the flow path of the FACSort, each 
run was followed by extensive washing with bleach. FIG. 
4E, FIG. 4F and FIG. 4G show the cell fluorescence distri 
bution for the sorting runs. After only two rounds of growth 
and sorting, the fluorescence intensity of 79% of the cell 
population fell within the positive window. A similar enrich 
ment was reproducibly obtained in three independent Stud 
ies. These results were not due to a growth advantage of the 
cells expressing Lpp-Omp A(46-159) -ScF(digoxin), Since 
Successive regrowth of the input cell mixture in the absence 
of Sorting did not result in any detectable enrichment. 
To verify that the cells with the increased fluorescent 
signal after the final sorting step were indeed JM109/ 
pTX152, a sample of cells from the final round of FACS was 
plated on chloramphenicol plates and then replica plated on 
plates containing 100 lug/ml amplicillin. The pTX152 plas 
mid conferS resistance only to chloramphenicol whereas the 
plasmid pTX101 which is present in the control cells also 
confers resistance to amplicillin. Over 95% of all the colonies 
examined were chloramphenicol resistant and amplicillin 
Sensitive (cm, amp) consistent with the phenotype 












plasmid DNA was isolated from eight cm, amp-colonies 
and the presence of pTX152 was confirmed by restriction 
analysis. 
The above results demonstrate that E. coli displaying a 
recombinant antibody on its Surface can be recovered from 
at least a 10-fold excess of control E. coli simply by 
incubation with a fluorescent hapten and fluorescent acti 
Vated cell Sorting. Only two rounds of Sorting and regrowth 
of the Sorted cell population are needed for enrichment from 
a large excess of background. Sorting is both rapid and 
efficient. Using a low-end flow cytometer it is possible to 
sort 1x10 cells per hour when operated so that the cells pass 
through the laser beam Single file. Higher Sorting rates can 
be obtained with a larger model (up to 5x107 cells per hour) 
and even higher still by Sorting multiple cells at a time (at the 
expense of increased background that one would expect to 
be eliminated by resorting the Selected population). In 
addition, the Sorting of positive clones is essentially quan 
titative and is limited only by the accuracy of the flow 
cytometer which is of the order of 95% (Tanke & van der 
Keur, 1992.) 
Screening of an Antibody Library Generated by Random 
Mutagenesis 
The inventors contemplate the use of random mutagenesis 
to create an antibody library. Such a library might include 
antigen binding domains of a known antibody or antibodies 
that have catalytic properties. 
The majority of Specific contacts to bound hapten involve 
residues in the CDR 3 of both chains (Kuby, 1991). The key 
contact residues for the F portion of the 26-10 anti 
digoxin antibody/digoxin complex (Schildbach et al., 1993) 
have been determined from the X-ray crystal Structure. AS 
expected, these key contact residues are in the CDR 3 of 
both chains. 
PCR with degenerate oligonucleotide primers was 
employed to mutagenize the CDR 3 of both the heavy and 
light chains of the scF digoxin antibody. Many of the 
different techniques for PCR mutagenesis that have been 
reported (Innis, et al., 1990; Morrison & Desrosiers, 1993; 
Aiyar & Leis, 1993) would be useful for this strategy. The 
primers, as shown in FIG. 5, were designed to introduce 
random codons at the key contact residues. A library of 
1.6x10" was generated. 
The new library will be screened for mutants binding to 
haptens Such as trityl (triphenylmethyl) using a trityl 
fluorescein conjugate. Sorting with fluorescein-fluorescein 
conjugate will also be employed as a control to ensure that 
clones binding the fluorescein-trityl conjugate have speci 
ficity towards the trityl moiety. Cells that sort in the positive 
window following incubation with the Texas Red 
fluorescein conjugate and in the negative window when 
Screened with the trity1-fluorescein conjugate will be 
Selected for further Studies. Libraries can be generated from 
Virtually any antibody Sequence from which the gene is 
cloned. 
While it is advantageous to know the key contact residues, 
a random mutagenesis of CDR 3 for one or both chains may 
also be used to generate libraries. The resulting libraries can 
then be Screened for compounds where the antibody is 
difficult to generate by conventional means Such as toxic or 
chemically labile compounds. 
This Strategy will also be useful to generate human 
antibodies for immunotherapy. A human antibody may be 
Subjected to mutagenesis and the resulting library Screened 
for antibodies against a particular antigen. This is a particu 
larly important Strategy since it is not general practice to 
immunize humans with potentially dangerous compounds 
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for the production of antibodies. Laboratory animals. Such as 
mice or rabbits will be hyperimmunized with a selected 
antigen and the antibodies isolated from the Spleen which is 
a rich Source of antibody producing cells. However, even 
those compounds used to generate antibodies in humans can 
only be isolated in relatively Small quantities from periph 
eral blood. Many attempts have been made to reproduce 
monoclonal antibodies in humans (Persson et al., 1991; 
Mullinax et al., 1990) including the production of human 
ized antibodies that have been generated (Winter & Milstein, 
1991) using a mouse variable loops on human constant 
regions. Significant problems may arise when a modified 
antibody is placed in a human due to the presence of 
non-human Sequences within the construct. 
The antibodies generated using the methods disclosed by 
the inventors will have a distinct advantage over previously 
reported methods of generating human antibodies in that the 
antibody will have the entire Sequence derived from a 
human Source. 
EXAMPLE 3 
Surface Expression of Anti-digoxin incorporating a Protease 
Cleavage Site 
A construct Similar to that used for Surface expression of 
ScF (digoxin) can be modified to incorporate a protease 
cleavage Site. For example, the recognition Sequence of 
enterokinase (Asp)-Ile-Arg can be introduced in the Lpp 
OmpA(46-159)-scF, between the OmpA(46-159) and the 
ScF domains. The protease cleavage Site at the N-terminal 
of the scF antibody domain of the fusion protein is then 
used to release the scF antibody in soluble form following 
treatment of the cells with the appropriate proteolytic 
enzyme. Because the outer membrane of E. coli serves as a 
protective barrier to the action of externally added proteases, 
very few contaminating proteins will be present in the 
culture Supernatant. A Single colony expressing a desired 
Single chain F antibody can be grown in liquid media and 
harvested by centrifugation after overnight growth at 24 C. 
The cells are resuspended in buffer to maintain the pH 
approximately neutral. Protease added at appropriate con 
centrations to the fusion protein to be treated and incubated 
at least 4 hours at 4 C. will release the soluble single chain 
F. Subsequently the cell Suspension is centrifuged and the 
Supernatant containing the Solubilized Single chain F anti 
body is collected. 
To separate the cleaved, soluble scF antibody from the 
protease, as well as any E. coli trace contaminants, a His 
Sequence may be introduced at the C-terminus of the ScF 
using PCR amplification with the appropriate primers. Poly 
histidine tails bind Strongly to metals So that the fusion 
protein can be purified by immobilized metal-ion affinity 
chromatography (IMAC). The separation of the cleaved scF, 
antibody using is carried out as described by Georgiou, et al 
(1994). 
Lpp-Omp A(46-159) fusions are typically expressed at a 
high level, typically around 5x10" per cell. Thus the yield 
after protease treatment and IMAC is at least 2-3 mg of 
antibody per liter of Shake flask culture. 
EXAMPLE 4 
The Success of the immunoassay described in Example 1 
is dependent on the exposure of antibody binding site as it 
is expressed on the bacterial cell Surface. AS the data in this 
example indicate, the Single chain digoxin antibody 
expressed on the Surface of E. coli has a binding affinity for 
digoxin that is at least within an order of magnitude of the 











Exposure of ScF binding Site when expressed on cell 
Surface 
The ScF domain of the Lpp-OmpA-ScF(digoxin) fusion 
protein encoded by pTX152 was shown by ELISA to bind 
specifically to the hapten digoxin. Whole cell lysates from 
JM109/pTX152 and from JM109/pTX101 as control were 
incubated on microtiter wells that had been coated with 
either digoxin-conjugated BSA (digoxin-BSA) or unconju 
gated BSA. Subsequently, the wells were treated with anti 
bodies against the HSV peptide or 3-lactamase to detect 
Lpp-OmpA(46-159)-scF(digoxin) or Lpp-OmpA(46-159) 
-B-lactamase, respectively. FIG. 2A shows that lysates from 
JM198/pTX152 bound specifically to wells coated with 
digoxin-BSA but not to unconjugated BSA, whereas the 
lysates from the control strain, JM109/pTX101, did not give 
a signal with either. Thus, Lipp-OmpA(46-159)-scF 
(digoxin) is active and can bind to the hapten specifically. 
FIG. 2B shows the results of ELISAS using intact cells. 
Samples containing the same number of cells were used in 
all the Studies. Cells containing the control plasmid, 
pTX101, gave the same low Signal when incubated on 
microtiter wells coated with either unconjugated BSA or 
with digoxin-BSA. A similar weak signal was detected with 
JM109/pTX152 incubated on BSA-coated wells and is pre 
Sumably due to non-specific binding. In contrast, a much 
higher absorbance was evident in wells coated with the 
digoxin-BSA conjugate indicating that there are active 
fusion protein molecules on the cell Surface. 
The display of the active scF antibody on the cell surface 
was confirmed by fluorescence microscopy (FIG. 3B). 
JM109/pTX152 cells were grown overnight at 24° C., 
incubated with a 1x107M solution of a digoxin-FITC 
conjugate for 1 hour and washed. As shown in FIG. 3A and 
FIG. 3B, all of the cells visible with phase contrast micros 
copy gave a strong fluorescence Signal. In control Studies, 
when JM109/pTX101 cells were incubated with the same 
concentration of digoxin-FITC and then washed, none of the 
cells became fluorescently labeled. Furthermore, protease 
treatment drastically reduced the ability of the cells to bind 
fluorescein-digoxin judging from the generation of a signal 
detectable by FACS. 
The intensity of the fluorescence signal from JM109/ 
pTX152 was dependent on the cell growth temperature and 
was much higher for cultures grown at 24 C. instead of 37 
C. This was consistent with previous results showing that the 
amount of proteins expressed on the Surface of E. coli by 
fusion to Lpp-OmpA(46-159) increased as the temperature 
is decreased (Francisco et al., 1992; 1993). Assuming that 
the efficiency of Surface display in this case is similar to that 
of B-lactamase (Francisco et al., 1992), then at 24° C. 
virtually all the scrl antibody chains must be accessible on 
the cell Surface. 
Specific binding of Surface expressed scF, with labeled 
antigen Samples of 10 cells per ml from cultures grown at 
24°C. were incubated with digoxin-FITC at 107M, washed 
in buffer and diluted to 3x10 cells per ml prior to sorting. 
The samples were then analyzed using a FACSort flow 
cytometer. FIG. 4A and FIG. 4B show that the fluorescence 
intensity of JM101/pTX152 cells expressing a surface dis 
played recombinant antibody Specific for digoxin was Sub 
Stantially higher than the intrinsic background Signal of 
control E. coli cells. In the case JM101/pTX101 expressing 
Lpp-Omp A(46-159)--lactamase is used as a control. 
When JM109/pTX152 cells were preincubated with an 
excess of free digoxin prior to incubation with the digoxin 
FITC conjugate, the fluorescence intensity of the cells was 
the same as for the background (FIG. 4D). This specific 
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inhibition was also seen using fluorescence microScopy, and 
demonstrates that the Surface expressed ScF(digoxin) spe 
cifically binds the fluorescently labeled hapten in the binding 
Site and is not the result of nonspecific interactions. 
Treatment of intact cells with trypsin prior to incubation 
with digoxin-FITC almost completely eliminated the popu 
lation of fluorescently labeled cells detected by flow cytom 
etry (FIG. 4C). In gram-negative bacteria, the Outer mem 
brane Serves as a barrier to preclude the diffusion of large 
extracellular molecules Such as proteins. The action of 
trypsin is limited to the proteolysis of proteins exposed on 
the external Surface of E. coli (Kornacker & Pugsley, 1990). 
Thus, the above result provides further evidence that the 
active ScF(digoxin) is indeed accessible on the outer 
Surface, free to interact with molecules in Solution. 
The ScF(digoxin) binding sites appeared to be fully 
saturated at concentrations of digoxin-FITC above 107M. 
Appreciable fluorescent Signal was clearly detected even at 
digoxin-FITC concentrations of 10M. These results are 
consistent with a binding constant that is at least within an 
order of magnitude of the reported affinity of a soluble 
anti-digoxin scF, antibody (Huston et al., 1988). 
The Specific fluorescence of cells expressing Lpp-OmpA 
(46-159)-scF(digoxin) was at least 40 times higher than 
that of control cells. 
EXAMPLE 5 
This Example illustrates a Solid phase immunoassay using 
E. coli with anti-digoxin Single chain F displayed on the 
Surface. This immunoassay is demonstrated to be a Sensitive 
and quantitative technique. To facilitate the removal of the 
Surface expressed antibody following the reaction with 
antigen, the cells may be attached to a Solid Support Such as 
a membrane, dipstick or beads. 
Solid Phase Immunoassays 
Digoxin-FITC (The Binding Site Inc. (San Diego, Calif.) 
was diluted to a concentration of 20nM in PBS. Digoxin 
(Sigma, St. Louis, Mo.) was brought to a concentration of 1 
uM in PBS. 
The pTX152/JM109 cells were grown in LB overnight at 
37 C. then subcultured into fresh LB and grown overnight 
at room temperature. The cells were harvested and resus 
pended in PBS pH 7.4 at a concentration of 10" cells/ml, 
based on the O.D. oo to form a cell Stock. Some cells were 
also resuspended in 15% glycerol/water and stored at 70° C. 
Frozen cells yielded the same results as freshly prepared 
cells. 
The following reagents were transferred to a 1.5 ml 
microcentrifuge tube, 25 ul of 20 nM digoxin-FITC solution, 
0.5-50 ul of 1 uM digoxin and PBS to a final volume of 950 
lil. The mixture was vortexed briefly and pulsed in an 
Eppendorf microcentrifuge. A 25 ul or 100 ul aliquot of the 
cell stock (10" cells/ml) was added to the mixture and 
allowed to incubate for 1 hour at room temperature. Fol 
lowing this incubation the cells were spun in a microcen 
trifuge for 5 minutes at 5,000 rpm and the Supernatant 
collected. The fluorescence of the digoxin-FITC in the 
Supernatant was measured using a fluorimeter. 
This immunoassay was also performed with the cells 
attached to a Solid Support. The Solid Support was Fisher 
filter paper P5 was cut into strips approximately 0.5 cmx2 
cm, and dampened in PBS by Submerging one end of the 
filter paper and allowing it to move upward. The filter paper 
was allowed to dry slightly and 10 ul of a Solution containing 
6x10 cells/ml was applied to the filter paper. The cells were 
fixed to the paper with a solution of 6-PLP, 8% PFA and 











700 mM NaCl, 50 mM KC1, 700 mM Lysine-HCl, 50 mM 
MgCl, and 70 nM EGTA followed by 0.01M MgCl, and 
8% PFA. The 8% PFA was prepared by addition of 4 g of 
PFA into 50 ml of water, followed by heating the solution to 
70° C. with constant stirring. Approximately 2 drops of a 1M 
Solution of NaOH was added to the Solution until it became 
clear. The solution was then filtered through Whatman filter 
paper #1, allowed to cool and stored at 4 C. until use. The 
final fixative Solution was produced by mixing the compo 
nents A, B and C to a final volume of 10 ml just prior to use, 
where A is 1 ml 6-PLP, 04 g sucrose and 3.03 ml water; B 
is 21.4 mg. NaIO; and C is 4.62 ml 8% PFA. The fixative 
was applied dropwise to one end of the filter paper and 
allowed to Soak upwards. The exceSS fixative was allowed to 
drain and the filter paper was washed twice with a Solution 
of 100 mM NHCl. The filter paper can then be stored in a 
Solution of PBS until use. 
The assay was performed by removing the filter paper 
with the cells attached and then measuring fluorescence of 
the Solution. 
ESSentially quantitative assays for an antigen can be run 
using a mixture of a known amount of labeled antigen 
combined with an unknown amount of unlabeled antigen. In 
one exemplary study, pTX152/JM109 with antidigoxin anti 
body displayed on the Surface were grown in LB Overnight 
at 37 C., Subcultured into fresh LB and grown overnight at 
room temperature. The cells were pelleted and resuspended 
in PBS to form a stock Solution of cells at a concentration of 
1x10" cells/ml. A mixture of 25ul of 20 nm digoxin-FITC 
and an amount of 1 M free digoxin in the range of 0.5-50 
lil, was prepared and brought to a final volume of 950 ul with 
PBS. A 25 ul or a 100 ul aliquot of the cell stock solution was 
added to the mixture to give a total of 0.25x10' or 1x10 
cells. The mixture was then allowed to incubate at room 
temperature for 1 hour. The cells were pelleted and the 
fluorescence of the Supernatant was measured for each 
Sample. 
FIG. 6 shows a plot of the residual fluorescence observed 
with the indicated amount of free digoxin, 0.5 nM digoxin 
FITC conjugate and either 250 million or 1 billion cells 
expressing the antidigoxin Single chain antibody on their 
Surface. 
To facilitate the removal of the Surface expressing anti 
body cells following the reaction, the cells may be attached 
to a Solid Support. In this example the Solid Support consisted 
of a membrane however many other Supports would work as 
well Such as dipSticks or beads. 
Strips of filter paper were moistened with PBS and 
allowed to dry slightly. A 10 ul aliquot of a 6x10 cells/ml 
of a cell suspension containing pTX152/JM109 cells dis 
playing anti-digoxin antibodies on their Surface was applied 
to the Strips of pre-moistened filter paper. The cells were 
then fixed to the paper using a mixture of 6-PLP, PFA and 
NaIO, as described in the materials and methods, and 
washed twice with a solution of 100 mM NHCl. Following 
the incubation no centrifugation is necessary the filter paper 
is simply removed from the solution and the residual fluo 
rescence measured as described previously. 
The assays described in this example use fluorescence as 
the indicator of binding; however, other indicator reactions 
may be used Such as radioactivity, enzyme conjugates and 
when the Surface expressed antibody is catalytic, an assay 
for catalytic activity may be used. 
EXAMPLE 6 
Electrochemiluminescence Detection 
Electrochemiluminescence (ECL) is also contemplated as 
a detection technique for immunoassayS. ECL involves the 
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indirect electrochemical excitation of certain molecules, 
usually Ru(bipy) + derivatives, that then relax back to 
ground State by emitting light. The amount of light is 
measured, thus providing a quantitative assay. There are 
Some advantages of ECL detection. First, the electrode can 
be tuned to different potentials so that only the desired 
molecules can be excited, even in the presence of many 
different chemical Species. Second, Since the ECL measure 
ments are carried out in the dark, there is no background 
Signal of light. Thus, ECL, like regular chemiluminescence, 
is highly sensitive (down to 200 fmol/L have been detected) 
(Blackburn et al., 1991). 
Except for the use of an electroluminescent molecule, the 
procedures are analogous to the procedures for competitive 
immunoassays described in Example 1. An analyte molecule 
is covalently attached to Ru(bipy)+. Known amounts of 
this conjugate will then be used in competition Studies with 
the unknown Sample of the analyte. Following equilibration 
and removal of cells (simple centrifugation of cells or 
removal of dipstick, beads, etc.), ECL will be used to 
quantitate the Ru(bipy)+ left in solution. This quantity will 
be proportional to the amount of analyte in the original 
unknown Solution. 
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SEQUENCE LISTING 
( 1) GENERAL INFORMATION: 
( i i i ) NUMBER OF SEQUENCES: 6 
( 2) INFORMATION FOR SEQ ID NO:1: 
( i) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH: 260 amino acids 
(B) TYPE: amino acid 
(D) TOPOLOGY: linear 
( i i ) MOLECULETYPE: protein 
( x i ) SEQUENCE DESCRIPTION: SEQ ID NO:1: 
G 1 u V a 1 G 1 in Le u G 1 in G 1 in Ser G 1 y Pro 
1. 5 
S e r V a 1 Arg Me t S e r Cy s Lys S e r S e r 
2 O 25 
Ty r Me t As n Tr p V a 1 Arg G | n Ser H is 
3 5 4 O 
G 1 y Ty r I 1 e Ser Pro Ty r S e r G 1 y V a 1 
5 5 5 
Lys G 1 y Lys A la Thr Le u Thr V a As p 
65 7 O 
Me t G 1 u Le u Arg Ser Le u Thir Ser G 1 u 
8 5 
A a G 1 y Se r S e r G 1 y As n Lys T r p A 1 a 
1 O O 1 O 5 
A 1 a Ser V a 1 T hr V a 1 Ser Ser G 1 y G 1 y 
1 15 1 2 O 
Ser G 1 y G y G 1 y G 1 y Ser A s p I le V a 1 
13 O 1 35 
Le u A 1 a V a 1 Ser Le u G 1 y G 1 m A rig A 1 a 
G 1 u Le u V a l Lys Pro G 1 y A 1 a 
1 O 1 5 
G 1 y Ty r I 1 e Phe T h r A s p P he 
3 O 
G 1 y Lys Ser Le u A s p Ty r I 1 e 
4 5 
Thr G 1 y Ty r A s in G 1 in Lys P he 
6 O 
Lys S e r S e r S e r Th r A a Ty r 
7 5 8 
A s p S e r A 1 a V a 1 Tyr Ty r Cy s 
9 O 9 
Me t A s p Ty r T r p G 1 y H is G 1 y 
1 1 O 
G 1 y G 1 y Ser G 1 y G 1 y G 1 y G 1 y 
1 2 5 
Le u Thr G in S e r P r o A a Se r 
1 4 O 




1 4 5 1 5 O 
G l n Ser Le u V a H is Ser As n G 1 y As 
1 65 
G 1 in Lys Pro G 1 y G 1 in Pro Pro Lys Le 
18 O 18 
A rig Phe Ser G 1 y V a l Pro A la Arg Ph 
21 O 2 15 
2 25 23 O 
2 4 5 
2 6 O 
( 2) INFORMATION FOR SEQ ID NO:2: 
( i) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH: 54 base pairs 
(B) TYPE: nucleic acid 
(C)STRANDEDNESS: single 
(D) TOPOLOGY: linear 
( i x ) FEATURE: 
(A) NAMEKEY: modified base 
(B) LOCATION: 25.27 
( D.) OTHER INFORMATION: ?mod base=OTHER 
f note= “N= C, A, G, or T 
( i x ) FEATURE: 
(A) NAMEKEY: modified base 
(B) LOCATION: 31.33 
( D.) OTHER INFORMATION: ?mod base=OTHER 
f note= “N= C, A, G, or T 
( i x ) FEATURE: 
(A) NAMEKEY: modified base 
(B) LOCATION: 46.48 
( D.) OTHER INFORMATION: ?mod base=OTHER 
f note= “N = C, A, T, or G 
( xi ) SEQUENCE DESCRIPTION: SEQ ID NO:2: 
CA GA G T G C C A T G A C C C CAAT AAT CNN N G GC NNNTTT G T TA C C A GANN N G C C G GC 
( 2) INFORMATION FOR SEQ ID NO:3: 
( i) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH: 35 base pairs 
(B) TYPE: nucleic acid 
(C)STRANDEDNESS: single 
(D) TOPOLOGY: linear 
( i x ) FEATURE: 
(A) NAMEKEY: modified base 
(B) LOCATION: 24.26 
( D.) OTHER INFORMATION: ?mod base=OTHER 
f note= “N = G, A, C, or T 
( xi ) SEQUENCE DESCRIPTION: SEQ ID NO:3: 
CAGGGTA CAT TTT CA C C GAC TT CNN N AT GA AT T G G 
( 2) INFORMATION FOR SEQ ID NO:4: 
( i) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH: 18 base pairs 
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18 O 18 5 1 9 O 
CGA TT C T C T G GA GT C C C T G C C A G G T T C A G T G G C A G T G G G T C T G A G T CA 6 24 
A rig Phe Ser G 1 y V a l Pro A la Arg Phe Ser G 1 y Ser G 1 y Ser G 1 u Sle r 
1 9 5 2 O O 2 O 5 
GAC TT C A C C C T C A C C AT C GAT C C T G T G GAG GAA GAT GAT G C T G CA. ATA 6 7. 2 
A s p Phe Thr Le u Thir I 1 e A s p Pro V a 1 G 1 u G 1 u A s p A s p A 1 a. A la I e 
21 O 2 15 22 O 
TAT TAC T G T A G C CAA ACT A C G CAT G T T C C A C C C A C G T T C G G C T C G G G G 7 2 O 
Ty r Ty r Cy s Ser G 1 in Th r T hr H is V a 1 Pro Pro T hr P he G 1 y Ser G 1 y 
2 25 23 O 23 5 24 O 
A C C A A G C T G G A G C T G AAA C G T G CT A G C C A G CCA GAA CT C G C C C C G GAA 7 6 8 
Th r Lys Le u G 1 u Le u Lys A rig A a Ser G 1 in Pro G 1 u Le u A 1 a Pro G 1 u 
2 4 5 25 O 25 5 
GA C C C C GAG GAC 
A s p Pro G 1 u As p 
2 6 O 
What is claimed is: 
1. A method for binding an analyte, comprising the Steps 
of: 
(a) obtaining a host cell that expresses from a vector 
within Said host cell an anti-analyte antibody or 
analyte-combining antibody fragment on the Surface of 
the host cell; and 
(b) contacting said host cell with a sample Suspected of 
containing an analyte that binds to Said anti-analyte 
antibody or analyte-combining antibody fragment 
under conditions effective to allow the formation of an 
antibody/analyte complex. 
2. The method of claim 1, further defined as a method for 
removing an analyte from a Sample, the method comprising 
contacting Said host cell with a Sample containing an 




7 8 O 
3. A method for binding an analyte, comprising the Steps 
of: 
(a) obtaining a gram negative bacterial host cell that 
expresses from a vector within Said host cell, an anti 
analyte antibody or analyte-combining antibody frag 
ment on the Surface of the host cell; and 
(b) contacting said host cell with a sample Suspected of 
containing an analyte that binds to Said anti-analyte 
antibody or analyte-combining antibody fragment 
under conditions effective to allow the formation of an 
antibody/analyte complex. 
4. The method of claim 3, further defined as a method for 
removing an analyte from a Sample, the method comprising 
contacting Said host cell with a Sample containing an 
unwanted analyte and obtaining the Sample free from Said 
complexed analyte. 
